

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-KSB

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the fiscal year ended December 31, 2004

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number 0-15888

IGENE Biotechnology, Inc.

(Name of Small Business Issuer in Its Charter)

Maryland

(State of other jurisdiction of incorporation or organization)

52-1230461

(IRS Employer Identification No.)

9110 Red Branch Road, Columbia, Maryland

(Address of principal executive offices)

21045

(Zip Code)

(410) 997-2599

(Issuer's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of Each Class

None

Name of Each Exchange on Which Registered

None

Securities registered pursuant to Section 12(g) of the Exchange Act:

Common Stock (par value \$.01 per share)

(Title of class)

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES NO

Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B contained in this form, and no disclosure will be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB.

State issuer's revenues for its most recent fiscal year \$ 0

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was sold, or the average bid and asked price of such common equity, as of a specified date within the past 60 days. \$2,958,931 as of August 30, 2005
(Note: The officers and directors of the issuer are considered affiliates for purposes of this calculation.)

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date. As of August 30, 2005 there were 101,732,453 shares of the issuer's common stock outstanding.

CAUTIONARY STATEMENT FOR PURPOSES OF “SAFE HARBOR PROVISIONS” OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995:

EXCEPT FOR HISTORICAL FACTS, ALL MATTERS DISCUSSED IN THIS REPORT, WHICH ARE FORWARD LOOKING, INVOLVE A HIGH DEGREE OF RISK AND UNCERTAINTY. CERTAIN STATEMENTS IN THIS REPORT SET FORTH MANAGEMENT’S INTENTIONS, PLANS, BELIEFS, EXPECTATIONS OR PREDICTIONS OF THE FUTURE BASED ON CURRENT FACTS AND ANALYSES. WHEN WE USE THE WORDS “BELIEVE,” “EXPECT,” “ANTICIPATE,” “ESTIMATE,” “INTEND” OR SIMILAR EXPRESSIONS, WE INTEND TO IDENTIFY FORWARD-LOOKING STATEMENTS. YOU SHOULD NOT PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS. ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE INDICATED IN SUCH STATEMENT, DUE TO A VARIETY OF FACTORS, RISKS AND UNCERTAINTIES. POTENTIAL RISKS AND UNCERTAINTIES INCLUDE, BUT ARE NOT LIMITED TO, COMPETITIVE PRESSURES FROM OTHER COMPANIES AND WITHIN THE BIOTECH INDUSTRY, ECONOMIC CONDITIONS IN THE COMPANY’S PRIMARY MARKETS, EXCHANGE RATE FLUCTUATIONS, REDUCED PRODUCT DEMAND, INCREASED COMPETITION, INABILITY TO PRODUCE REQUIRED CAPACITY, UNAVAILABILITY OF FINANCING, GOVERNMENT ACTION, WEATHER CONDITIONS AND OTHER UNCERTAINTIES, INCLUDING THOSE DETAILED IN “RISK FACTORS” BELOW AND FROM TIME-TO-TIME IN THE COMPANY’S SECURITIES AND EXCHANGE COMMISSION FILINGS.

PART I

ITEM 1. DESCRIPTION OF BUSINESS

General

IGENE Biotechnology, Inc. (“Igene”) is engaged in the business of developing, marketing, and manufacturing specialty ingredients for human and animal nutrition. Igene was formed on October 27, 1981 to develop, produce and market value-added specialty biochemical products. Igene is a supplier of natural astaxanthin, an essential nutrient in different feed applications and as a source of pigment for coloring farmed salmon species. Igene also supplies nutraceutical ingredients, including astaxanthin. Igene is focused on fermentation technology, nutrition and health in its marketing of products and applications worldwide.

Igene has devoted its resources to the development of proprietary processes to convert selected agricultural raw materials or feedstocks into commercially useful and cost effective products for the food, feed, flavor and agrochemical industries. In developing these processes and products, Igene has relied on the expertise and skills of its in-house scientific staff and, for special projects, various consultants.

During the year 2000, Igene formed a wholly owned subsidiary, Igene Chile Comercial, Ltda., in Chile. The subsidiary has a sales and customer service office in Puerto Varas, Chile, and a product warehouse in Puerto Montt, Chile.

During the year 2001, Igene purchased its sales agent, ProBio Nutraceuticals AS (“ProBio”), a Norwegian company. ProBio specializes in sales and marketing to the pharmaceutical industry and feed ingredients markets. In addition to ProBio’s nutraceuticals business, it was hoped the purchase would add to Igene’s management structure and enhance sales development. Following the acquisition, Stein Ulve and Per Benjaminsen, the managing director and director of marketing and sales, respectively, of ProBio became our chief executive officer and chief marketing officer, respectively, pursuant to written employment agreements. This division was referred to as Igene Norway AS.

Igene Biotechnology Inc., in an effort to focus on and grow its core business, on February 5, 2003 disposed of its interest in its former subsidiary, ProBio. Fermtech AS, a joint stock company incorporated in the Kingdom of Norway and owned equally by our former chief executive officer, Stein Ulve and our former chief marketing officer, Per Benjaminsen, purchased the shares of ProBio. Mr. Ulve has resigned as CEO and director of Igene while Mr. Benjaminsen continues to serve the Company as Director of Sales and Marketing, effective as of December 31, 2002.

Igene currently leases manufacturing capacity in Mexico City, Mexico, through a contract manufacturer on an as needed basis. In an effort to develop a dependable source of production, on March 19, 2003, Tate & Lyle PLC and Igene Biotechnology, Inc announced a 50:50 joint venture to produce AstaXin® for the aquaculture industry. Production utilizes Tate & Lyle's fermentation capability together with the unique technology developed by Igene. Part of Tate & Lyle's existing Selby, England, citric acid facility will be modified to include the production of 1,500 tons per annum of this product. Tate & Lyle's investment of \$25 million includes certain of its facility assets currently used in citric acid production. The production facility is generating product and it is hoped the facility will be complete and in full production by the end of the calendar year 2005.

Government Regulation

The manufacturing and marketing of most of the products Igene has developed are, and will likely continue to be, subject to regulation by various governmental agencies in the United States, including the Food and Drug Administration ("FDA"), the Department of Agriculture ("USDA"), the Environmental Protection Agency ("EPA"), and comparable agencies in other countries. Igene, as a matter of policy, requires that its products conform to current Good Manufacturing Practices ("GMPs") (as defined under the Federal Food, Drug and Cosmetic Act and the rules and regulations thereunder) and Igene believes all of its products so conform. The extent of any adverse governmental regulation that might arise from future administrative or legislative action, including current rules and regulations pertaining to the process of GRAS (Generally Recognized as Safe) affirmations, cannot be predicted.

In a notice published in the Federal Register July 6, 2000, the FDA announced the amendment of its color additive regulations to provide for the safe use of Phaffia yeast, such as that in the Company's product, AstaXin®, as a color additive in aquaculture feeds. This ruling, which became effective August 8, 2000, allows Igene to market its product, AstaXin®, for aquaculture feeds and fish produced in, or imported into, the United States. This ruling is available to the public in the Federal Register. Igene has also previously obtained approval for AstaXin® from the Canadian Food Inspection Agency (CFIA). Additional foreign approval applications for AstaXin®, including those for the European Union, are in progress. Igene is required to perform additional tests and prepare additional documentation as part of the application process. The initial application was submitted in May of 2004. It is hoped the application will be approved in the latter half of 2005.

In July 2000, Igene also obtained clearance from the FDA to market its product, AstaXin®, as a human dietary supplement in the United States. Scientific literature indicates that natural astaxanthin, such as that in the Company's product, AstaXin®, may offer health benefits for humans due to its antioxidant properties. The FDA notification and the Company's submissions are available to the public from the FDA. Comparable agencies in the European Union and other foreign countries may have their own additional registration procedures. No additional applications for approval of AstaXin® as a human nutritional supplement have yet been submitted.

Igene has not incurred and does not anticipate any material environmental compliance costs.

Research and Development

As of December 31, 2004, Igene had expended approximately \$14,622,000 on research and development since its inception on October 27, 1981 and has, as of December 31, 2004, recognized its share in revenues, directly or through the Joint Venture, from product sales and royalties of approximately \$14,500,000 from the proprietary processes resulting from such research and development. Igene will continue to incur research and development costs in connection with improvements in its existing processes and products, but it does not anticipate development of new processes and products in 2005.

Research and development expenditures for each of the last two years are as follows:

2004	\$ 847,544
2003	\$ 745,364

Igene's research and development activities have resulted in the development of processes to produce the products hereinafter discussed.

Commercial Products

AstaXin®

AstaXin® is Igene's registered trademark for its dried yeast product made from a proprietary strain of yeast developed by Igene. AstaXin® is a natural source of astaxanthin, a pigment which imparts the characteristic red color to the flesh of salmon, trout, prawns and certain other types of fish and shellfish. In the ocean, salmon and trout obtain astaxanthin from krill and other planktonic crustaceans in their diet. A krill and crustacean diet would be prohibitively expensive for farm-raised salmonids. Without the addition of astaxanthin, the flesh of such fish is a pale, off-white color, which is less appealing to consumers expecting "salmon-colored" fish. Fish feeding trials in Europe, Asia, and North and South America have demonstrated the efficacy of AstaXin® in pigmenting fish. An estimated 1,000,000 metric tons of farm-raised salmon are produced annually worldwide. Igene derived revenue during 2004 and 2003 from sales of AstaXin® (including sales made by the Joint Venture) of which the majority were to fish producers in the aquaculture industry in Chile, as well as sales exported to Japan and Canada.

On May 20, 2000, Igene renewed its manufacturing arrangement with Fermic, S.A. de C.V., of Mexico City, Mexico ("Fermic"), for the production of its natural astaxanthin pigment, AstaXin®, in Fermic's manufacturing facility in Mexico. Commercial production began in January of 1998.

The Fermic contract executed in May 2000, provides that the manufacturer has the non-exclusive right and license to produce AstaXin® for Igene, is paid a cash fee based on manufacturing capacity, and may receive up to 20,000,000 shares of Igene common stock in lieu of additional cash based on quantity of product manufactured over the six year term. Of the 20,000,000 shares available to be earned, 14,730,014 have been earned to date. Fermic provides equipment and facilities necessary to manufacture and store the product and is responsible for purchasing raw materials. Igene is responsible for sales efforts and for ensuring the quality of the pigment. Igene also has a role in ensuring that the manufacturing process works effectively. The contract expires May 20, 2006, unless terminated earlier by either party. See Item 2. Description of Property.

On March 18, 2003, the Company entered into a Joint Venture Agreement with Tate & Lyle Fermentation Products Ltd. ("Tate") Pursuant to a Joint Venture Agreement, the Company and Tate agreed to form a joint venture (the "Joint Venture") to manufacture, market and sell Astaxanthin and derivative products throughout the world for all uses other than as a Nutraceutical or otherwise for direct human consumption. Tate contributed \$24,600,000 in cash to the Joint Venture, while the Company transferred to the Joint Venture its technology relating to the production of Astaxanthin and assets related thereto. These assets will continue to be used by the Joint Venture in the same manner as historically used by the Company. The Company and Tate each have a 50% ownership interest in the Joint Venture and equal representation on the Board of Directors of the Company. The initial value of the Company's investment in the Joint Venture has been recorded at an amount equal to the book value of the Company's consideration contributed at the creation of the Joint Venture. As the cost of the Company's technology and intellectual property has been previously expensed and had a carrying amount of zero, the investment in the Joint Venture has been initially recorded with a book value of \$316,869, which represents the unamortized production costs contributed to the Joint Venture. In addition to the Company's initial investment in the Joint Venture, the Company has made \$685,438 in advances to the Joint Venture and \$6,000 capital investment.

Production utilizes Tate's fermentation capability together with the unique technology developed by Igene. Part of Tate's existing Selby, England, citric acid facility will be modified to produce up to 1,500 tons per annum of this product. Tate & Lyle's investment of approximately \$25 million includes certain of its facility assets currently used in citric acid production.

Based on estimates of worldwide production of farm raised salmon, Igene believes the market for astaxanthin as a color additive in salmon feed exceeds \$200,000,000 per year worldwide, which would require approximately 10,000 metric tons of AstaXin® to serve 100% of the market. A single competitor, who produces a chemically synthesized product, presently controls more than 80% of the world market for astaxanthin as a pigment for aquaculture. The Joint Venture's production through the first half of 2005 has been limited by the development of the new facility, it is hoped the by the end of 2005 the Joint Venture will have successfully completed the new production facility. However, there can be no assurance that the Company and venture will be able to utilize these additional sources of production capacity, or that, if it is able to utilize the additional production capacity, that it will be able to do so on terms favorable to Igene or that any level of demand will continue.

Previously reported litigation (original lawsuit filed July 21, 1997, in the U.S. District Court, Baltimore, MD) between Archer Daniels Midland, Inc. ("ADM") and Igene, involving allegations of patent infringement and counterclaims concerning the theft of trade secrets was settled on September 29, 2003. ADM had requested injunctive relief as well as an unspecified amount of damages, and Igene had filed a \$300,450,000 counterclaim concerning the theft of trade secrets. Resolution of the dispute between ADM and Igene did not result in an unfavorable outcome to Igene. Accordingly, no liability was recorded on the balance sheet. Under the terms of the settlement, Igene is permitted to continue to make and sell its product, AstaXin®. See Item 3. Legal Proceedings.

During 2001 Igene began investigating other possible commercial uses of astaxanthin, including its application as a human nutritional supplement. Igene has formulated natural astaxanthin as a super-antioxidant, AstaXin®, for the North American dietary supplement market. Antioxidants are one of the largest product categories in the health and nutrition industry.

Patents and Trademarks

It is Igene's policy to protect its intellectual property rights by a variety of means, including applying for patents and trademarks in the United States and in other countries. Igene also relies upon trade secrets and improvements, un-patented proprietary know-how and continuing technological innovation to develop and maintain its competitive position. In this regard, Igene places restrictions in its agreements with third parties with respect to the use and disclosure of any of its proprietary technology. Igene also has internal nondisclosure safeguards, including confidentiality agreements with employees and consultants.

All patents and trademarks are carefully reviewed and those with no foreseeable commercial value are abandoned to eliminate costly maintenance fees. Patents, trademarks on technology and products with recognized commercial value, and which Igene is currently maintaining, include those for AstaXin®, which have remaining lives ranging from 4 to 8 years.

Competition

Competitors in the biotechnology field in the United States and elsewhere are numerous and include major chemical, pharmaceutical and food companies, as well as specialized biotechnology companies. Competition can be expected to increase as small biotechnology companies continue to be purchased by major multinational corporations with substantial resources. Competition is also expected to increase with the introduction of more diverse products developed by biotechnology firms, increasing research cooperation among academic institutions and large corporations, and continued government funding of research and development activities in the biotechnology field, both in the United States and overseas. Unlike the majority of biotechnology companies, which are developing products principally for the pharmaceutical industry, Igene has focused its own activities on the development of proprietary products for use in aquaculture and nutritional supplement industries. In the future, however, competitors may offer products, that, by reason of price, or efficacy, or more substantial resources for technology advances, may be superior to Igene's existing or future products.

A single large pharmaceutical company presently dominates the market for astaxanthin pigment for aquaculture in which Igene's product, AstaXin®, is presently marketed and sold. Igene believes that AstaXin®, which is made from yeast, will compete with this dominant producer, and other producers whose products are chemically synthesized, based on its use of natural ingredients. As consumers and producers of fish become more aware of other alternatives, Igene believes that they will desire natural ingredients, such as those in AstaXin®.

Several companies are also known to be developing and marketing other natural astaxanthin products. Some of these companies' products are made from algae, while others are made from yeast. Igene believes that AstaXin® will compete with other companies' astaxanthin products which are made from algae, due to Igene's higher production capacity and lower production costs, but can provide no assurances in that regard. Igene also believes that AstaXin® will compete with other companies' astaxanthin products which are also made from yeast due to our proprietary process to disrupt yeast cell walls, which, as studies have shown, makes AstaXin® more readily absorbed by the fish.

Igene is also beginning to explore the possible use of AstaXin® as a human nutritional supplement. This market is attractive because of potentially higher profit margins. Other companies are known to also be developing and marketing astaxanthin products for the human nutritional supplement market. Igene cannot yet predict how competitive it would be in this market.

Sources and Availability of Raw Materials

Raw materials used in the manufacture of AstaXin® consist principally of agricultural commodities widely available in world markets from many suppliers, which may be used interchangeably. We do not anticipate material price fluctuations or changes in availability in these raw materials in the near future.

Employees

At December 31, 2004, Igene had 12 full time employees. Three full time employees are in administration and/or marketing, while the remainder are engaged in research, process development and support of manufacturing activities. The full time marketing employees include one representative in Norway. The remainder of the employees are based in the U.S. Igene also utilizes various consultants on an as-needed or short-term basis.

None of Igene's employees are represented by a labor union and Igene has experienced no work stoppages. Igene believes its relations with its employees are satisfactory.

ITEM 2. DESCRIPTION OF PROPERTY

Igene leases approximately 8,500 square feet of space in the Oakland Ridge Industrial Park located at 9110 Red Branch Road, Columbia, Maryland. Igene occupies the space under a lease extension expiring on January 31, 2011. The approximate current rental expense is \$93,600. Approximately 2,000 square feet of this space is used for executive and administrative offices and approximately 2,500 feet is used for research and development activities. The remaining 4,000 square feet of space is used for Igene's intermediate-stage or scale-up pilot plant facility.

Igene also leases, under a contract expiring May 2006, manufacturing capacity at Fermic S.A. de C.V. (Fermic) in Mexico City, Mexico and leases warehouse space for product storage in Mexico City. The lease for warehouse space is on an as needed basis, and Igene is under no obligation to lease space.

Igene began a one year lease in December 2001, which renewed in December 2004, of approximately 220 square feet of office space, in Chile, to conduct marketing and technical support activities by its full-time technical representatives. Igene also leases warehouse space on a month-to-month basis as needed for product storage in Chile.

Igene currently owns or leases sufficient equipment and facilities for its research operations and all of this equipment is in satisfactory condition and is adequately insured. There are no current plans for improvement of this property. If demand for Igene's product continues to increase, Igene plans to lease additional warehouse space as needed in Chile.

ITEM 3. LEGAL PROCEEDINGS

Previously reported, litigation (original lawsuit filed July 21, 1997, in the U.S. District Court, Baltimore, MD) between Archer Daniels Midland, Inc. ("ADM") and Igene, involving allegations of patent infringement and counterclaims concerning the theft of trade secrets was settled on September 29, 2003. ADM had requested injunctive relief as well as an unspecified amount of damages, and Igene had filed a \$300,450,000 counterclaim concerning the theft of trade secrets. Resolution of the dispute between ADM and Igene did not result in an unfavorable outcome to Igene. Accordingly, no liability was recorded on the balance sheet. Under the terms of the settlement, Igene is permitted to continue to make and sell its product, AstaXin®. Igene had expenses of \$40,580 and \$133,464 in 2004 and 2003 respectively, associated with the resolution of this litigation.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

PART II

ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.

Common Stock

Commencing on or about June 12, 1989, Igene's common stock began trading on the over-the-counter market on a limited basis and is quoted on the National Quotation Bureau's OTC "bulletin board". The following table shows, by calendar quarter, the range of representative bid prices for Igene's common stock for the first two quarters of 2005, as well as 2004 and 2003.

	<u>Calendar Quarter</u>	<u>High</u>	<u>Low</u>
2005:	First Quarter	\$.1170	\$.0650
	Second Quarter	\$.1000	\$.0300
2004:	First Quarter	\$.2100	\$.1000
	Second Quarter	\$.2000	\$.0950
	Third Quarter	\$.1050	\$.0700
	Fourth Quarter	\$.1300	\$.0600
2003:	First Quarter	\$.1000	\$.0070
	Second Quarter	\$.0800	\$.0400
	Third Quarter	\$.0700	\$.0200
	Fourth Quarter	\$.2100	\$.0600

Igene obtained the above information through Pink Sheets, LLC, a national quotation bureau. Such quotations are inter-dealer quotations without retail mark-up, mark-downs, or commissions, and may not represent actual transactions. The above quotations do not reflect the "asking price" quotations of the stock.

The approximate number of record holders of Igene's common stock as of August 19, 2005 was 250. As of August 19, 2005, the high bid and low offer prices for the common stock, as shown on the "over-the-counter bulletin board" were \$0.05 and \$0.045, respectively.

Dividend Policy

When and if funds are legally available for such payment under statutory restrictions, Igene may pay annual cumulative dividends on the preferred stock of \$.64 per share on a quarterly basis. During 1988 Igene declared and paid a cash dividend of \$.16 per share on its preferred stock. In December 1988, Igene suspended payment of the quarterly dividend of \$.16 per share of preferred stock. No dividends have been declared or paid since 1988. Any resumption of dividend payments on preferred stock would require significant improvement in cash flow. Preferred stock dividends are payable when and if declared by Igene's board. Unpaid dividends accumulate for future payment or addition to the liquidation preference and redemption price of the preferred stock. As of December 31, 2004, total dividends in arrears on Igene's preferred stock equal \$192,494 (or \$10.40 per share) on Igene's Series A and are included in the carrying value of the redeemable preferred stock.

Dividends on common stock are currently prohibited because of the preferential rights of holders of preferred stock. Igene has paid no cash dividends on its common stock in the past and does not intend to declare or pay any dividends on its common stock in the foreseeable future.

Sales of Unregistered Securities

On April 4, 2004, the Board of Directors, authorized the payment of 250,000 common shares to the Company's attorney in connection with the settlement of the ADM matter. These shares were issued at an estimated value of \$.11 per share, aggregating \$27,500. The costs were expensed in the second quarter as part of the ADM

legal expense. Igene relied on Section 4(2) of the Securities Act of 1933, as amended, to issue the shares to its attorney without registration under the Securities Act of 1933, as amended.

During the course of 2004, Fermic, Igene's manufacturing agent, earned 3,640,792 shares of common stock as part of the manufacturing agreement. Fermic earns 2,250 shares of common stock for each kilogram pure astaxanthin produced and delivered as part of the agreement. The average price is based on the market value of the shares at the time the product was produced. Fermic can earn up to 20,000,000 shares in total under the contract. The 3,640,792 shares were earned at an average price of \$.11 per share for 2004. Through December 31, 2004, 14,730,014 shares have been earned. Any future shares earned by Fermic will be issued on a quarterly basis. Igene relied on Section 4(2) of the Securities Act of 1933, as amended, to issue the shares to Fermic without registration under that act. Igene relied on the representations and warranties of Fermic made in the manufacturing agreement in claiming the aforementioned exemption.

During the course of 2004, \$295,000 of the \$1,000,000 of Convertible Debentures issued as part of the 2001 ProBio purchase, were converted to common stock. These shares were converted at \$.10 per share for a total of 2,950,000 shares. These shares were issued and the notes cancelled. This relieved the Company of \$295,000 of long-term debt. Igene relied on Section 4(2) of the Securities Act of 1933, as amended, to issue the shares to the holders converting these debentures without registration under that act.

ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

Certain statements in this report set forth management's intentions, plans, beliefs, expectations or predictions of the future based on current facts and analyses. Actual results may differ materially from those indicated in such statements, due to a variety of factors including competitive pressures from other companies and within the biotech industry, economic conditions in Igene's primary markets, exchange rate fluctuations, reduced product demand, increased competition, unavailability of production capacity, unavailability of financing, government action, weather conditions and other uncertainties, including those detailed in "Risk Factors" below and from time-to-time in Igene's Securities and Exchange Commission filings.

Results of Operations

On March 18 2003, the Company entered into a Joint Venture Agreement with Tate & Lyle Fermentation Products Ltd. ("Tate"). Pursuant to a Joint Venture Agreement, the Company and Tate agreed to form a joint venture (the "Joint Venture") to manufacture, market and sell Astaxanthin and derivative products throughout the world for all uses other than as a Nutraceutical or otherwise for direct human consumption. Tate contributed \$24,600,000 in cash to the Joint Venture, while the Company transferred to the Joint Venture its technology relating to the production of Astaxanthin and assets related thereto. These assets continue to be used by the Joint Venture in the same manner as historically used by the Company. The Company and Tate each have a 50% ownership interest in the Joint Venture and equal representation on the Board of Directors of the Company. The initial value of the Company's investment in the Joint Venture has been recorded at an amount equal to the book value of the Company's consideration contributed at the creation of the Joint Venture. As the cost of the Company's technology and intellectual property has been previously expensed and has a carrying amount of zero, the investment in the Joint Venture has been recorded with a book value of \$316,869, which represents the unamortized production costs contributed to the Joint Venture. Added to this was a purchase of common stock in the new venture of \$6,000.

Production will utilize Tate's fermentation capability together with the unique technology developed by Igene. Part of Tate's existing Selby, England, citric acid facility will be modified to produce up to 1,500 tons per annum of this product. Tate's investment of approximately \$25 million includes certain of its facility assets currently used in citric acid production. Sales and cost of sales activity are now recorded as part of the operations of the unconsolidated venture.

As a result of the Joint Venture, the production, sales and marketing of Astaxanthin now takes place in the unconsolidated Joint Venture. From inception on March 18, 2003 through December 31, 2004, the Joint Venture's results of operations included the following: Gross profit from inception was a negative \$4,356,000 on sales of \$6,784,000, less manufacturing cost of \$11,140,000. Selling and general and administrative expenses were

\$5,268,000 and interest expense was \$151,000. The resulting loss was \$9,775,000. Igene's 50% portion of the Joint Venture loss was \$4,887,500.

Because the Company accounts for its investment in the Joint Venture under the equity method of accounting, it would ordinarily recognize a loss representing its 50% equity interest in the loss of the Joint Venture. However, losses in the Joint Venture are recognized only to the extent of the investment in and advances to the Joint Venture. Losses in excess of this amount are suspended from recognition in the financial statements and are carried forward to offset Igene's share of the Joint Venture's future income, if any.

At December 31, 2004, prior to the recognition of its portion of the Joint Venture loss, Igene's investment in the Joint Venture consisted of \$322,869 and its net advances to the Joint Venture amounted to \$685,438, for a total of \$1,008,307. For the year ended December 31, 2003, Igene recognized \$818,052 of its share of a \$914,494 loss. For the year ended December 31, 2004, Igene recognized losses to the extent of the increase in advances of \$190,255. The remainder, of approximately 3.9 million, is suspended and will be carried forward to offset Igene's share of earnings from the Joint Venture, if any. The balance in the Advances to and Investment in Joint Venture account on the Company's financial statements is zero at December 31, 2004.

The following schedules display certain account balances of the joint venture as of December 31, 2004 and for the period since March 18, 2003 (inception):

	December 31, <u>2004</u> (Unaudited)
ASSETS	
CURRENT ASSETS	
Cash	\$ 1,769,000
Accounts Receivable	1,602,000
Inventories	<u>1,434,000</u>
	4,805,000
OTHER ASSETS	
Fixed Assets	20,765,000
Intellectual property	<u>24,614,000</u>
TOTAL ASSETS	<u><u>\$ 50,184,000</u></u>
LIABILITIES AND EQUITY	
CURRENT LIABILITIES	
Accounts payable and accrued expenses	\$ 5,883,000
Working capital loan	<u>5,347,360</u>
TOTAL LIABILITIES	11,230,360
Equity	<u>38,953,640</u>
TOTAL LIABILITIES AND EQUITY	<u><u>\$ 50,184,000</u></u>

	Period from initial investment to <u>December 31, 2004</u> (unaudited)
Net Sales	\$ 6,784,000
Less: manufacturing cost	<u>(11,140,000)</u>
Gross Profit (Loss)	(4,356,000)
Less: selling, general and administrative	<u>(5,268,000)</u>
Operating Loss	(9,624,000)
Interest Expense	<u>(151,000)</u>
Net Loss	<u>\$ (9,775,000)</u>
Igene's 50% equity interest in the net loss	\$ (4,887,500)
Igene's Investment in and Advances to the Joint Venture	<u>\$ (1,008,307)</u>
Igene's suspended loss	<u>\$ (3,879,193)</u>

The following schedule displays certain account balances of the Joint Venture for the year ended December 31, 2004 and the period from the initial investment (March 18, 2003) to December 31, 2003. As shown, 50% of the activity is recorded as equity in loss of Joint Venture:

	Year Ended <u>December 31, 2004</u>	Period from March 18, 2003 to <u>December 31, 2003</u>
Net Sales	\$ 5,650,000	\$ 1,134,000
Less: manufacturing cost	<u>(9,989,000)</u>	<u>(1,151,000)</u>
Gross Profit (Loss)	(4,339,000)	(17,000)
Less: selling, general and admin	<u>(3,440,000)</u>	<u>(1,828,000)</u>
Operating Loss	(7,779,000)	(1,845,000)
Interest Expense	<u>(167,000)</u>	<u>16,000</u>
Loss before tax	<u>\$ (7,946,000)</u>	<u>\$ (1,829,000)</u>
50% equity interest Igene	<u>\$ (3,973,000)</u>	<u>\$ (914,494)</u>
Igene's additional Investment in and Advances to the Joint Venture	<u>\$ (190,255)</u>	<u>\$ (818,052)</u>
Igene's incremental suspended loss	<u>\$ (3,782,745)</u>	<u>\$ (96,442)</u>

Sales and other revenue

As part of the Joint Venture agreement, all sales of AstaXin® are recognized through the venture company. Therefore, Igene recorded no sales during 2004 or the last half of 2003. For 2003 sales were \$463,486. Sales had been limited in the past quarters due to insufficient production quantity. However, the primary cause for the decreased sales for the year as compared with the prior year is that, as of June, 2003, Igene had sold its remaining inventory to the Joint Venture in anticipation of the consummation of the Joint Venture Agreement. Management anticipates that the joint venture with Tate will provide a more dependable product flow. However, there can be no assurance of the dependability of production, or that any increases in production or sales will occur, or that if they occur, they will be material.

Cost of sales and gross profit

As with sales revenue, beginning July 2003 forward, cost of sales and gross profit are recognized and will continue to be recognized through the Joint Venture. Igene reported no gross profit on sales of AstaXin® for 2004 or the last half of 2003. Gross profit on sales of AstaXin® was \$17,342 for 2003. At the time of transition to the

Joint Venture, Igene's gross profit was at 9% of sales. The Company attributes the fall in gross profit to a combination of pricing pressure in the market and inefficiencies in production. Demand is expected to increase both due to seasonal increases in customer usage and increases in our market share. Management expects that sales and gross profits may be limited by the quantities of AstaXin® the Company is able to have produced by its current contract manufacturer, while the Joint Venture prepares for production. The Company believes that the lack of production capacity should be alleviated as the Joint Venture plant continues to develop in 2005. Unless augmented by increases in production resulting from the Joint Venture and increased production efficiency resulting from process research and development, sales and gross profit growth may be limited by production restrictions. Management expects the level of gross profit to improve in the future as a percentage of sales, with expected increases in production efficiency received from the Joint Venture with Tate offsetting pricing competition, but can provide no assurances in that regard to future increased production or future increased margin. Cost of sales for 2003 was \$446,144.

Marketing and selling expenses

Marketing and selling expenses for 2004 were \$326,689, a decrease of \$1,704, of less than one percent from the marketing and selling expenses of \$328,393 for 2003. As a result of the Joint Venture with Tate, Igene is expecting an increase in salable product with a corresponding increase in selling expenses at the point the new facility is in full production. However no assurances can be made in regards to increased production from the new facility nor the corresponding increase in selling expenses. All marketing and selling expenses incurred by Igene since the inception of the Joint Venture, with the exception of the cost related to the shares reissued to Fermtech as part of the ProBio agreement have been reimbursed by the Joint Venture. Approximately \$216,000 of the 2004 and \$181,000 of the 2003 marketing and selling expenses was reimbursed by the Joint Venture.

Research, development and pilot plant expenses

Research, development and pilot plant expenses for 2004 and 2003 were \$847,544 and \$745,364, respectively, reflecting an increase of \$102,180 or 13.7%. Costs increased in support of increasing the efficiency of the manufacturing process through experimentation in the Company's pilot plant, undertaken in an attempt to develop higher yielding strains of yeast and other improvements in the Company's AstaXin® technology, as well as through travel to the Selby facility to aid in bringing the plant to full production. Igene is hoping this will lead to an increase in salable product at a reduced cost to Igene and the Joint Venture. However, no assurances can be made in that regard. All \$847,000 research and development costs in 2004 were funded through reimbursement from the Joint Venture. During 2003, the Joint Venture reimbursed Igene approximately \$638,000 for the costs.

General and administrative expenses

General and administrative expenses for 2004 remained nearly constant with those of 2003 increasing less than 1 percent from \$687,427 to \$688,125. General and administrative expenses are expected to remain at the current level. These expenses are expected to be funded by additional funding from stockholders, and by cash flows from operations, to the extent available for such purposes. However, we can provide no assurances that such additional funding or cash flows from operations, will become available or that such funding, if any, will be available upon terms favorable to us. Of the general and administrative expenses incurred during 2004 approximately \$550,000 were reimbursed by the Joint Venture. During 2003, approximately \$398,000 were reimbursed by the Joint Venture.

Litigation expenses

Previously reported litigation (original lawsuit filed July 21, 1997, U.S. District Court, Baltimore, MD between Archer Daniels Midland, Inc. ("ADM") and Igene, involving allegations of patent infringement and counterclaims concerning the theft of trade secrets, was resolved on September 29, 2003. Resolution of the dispute between ADM and Igene did not result in an unfavorable outcome to Igene. Igene will continue to make and sell its product, AstaXin®. The Company incurred \$40,580 of litigation expenses for 2004 and \$133,464 for 2003.

Expenses reimbursement by Joint Venture

As part of the Joint Venture agreement, costs incurred by Igene related to production, research and development, as well as those related to the marketing of AstaXin(R), are considered costs of the Joint Venture and therefore are reimbursed by the Joint Venture. For the year ended December 31, 2004, costs reimbursed by the Joint Venture totaled \$1,612,845. Of the reimbursement received approximately \$847,000 was to cover research and development costs, \$216,000 was to cover marketing and selling expenses and \$550,000 was to cover general and administrative costs. For the year ended December 31, 2003, costs reimbursed by the Joint Venture totaled \$1,252,565. Of the reimbursement received approximately \$638,000 was to cover research and development costs, \$181,000 was to cover marketing and selling expenses, \$398,000 was to cover general and administrative costs, and the balance related to various production related expenses.

Interest expense (net of interest income)

Interest expense (net of interest income) for 2004 and 2003 was \$829,617 and \$965,737 respectively, a decrease of \$136,120 or 14%. This interest expense (net of interest income) was almost entirely composed of interest on Igene's long term financing from its directors and other stockholders and interest on Igene's subordinated and convertible debentures, and is expected to remain at the reduced level as the reduction of preferred shares outstanding has reduced the related accrued dividends recorded as interest.

Equity in earnings of Joint Venture

As a result of the Joint Venture, the production, sales and marketing of Astaxanthin now take place in the unconsolidated Joint Venture. For the years ended 2004 and 2003, Igene's portion of the Joint Venture loss was \$3,973,000 and \$914,494, respectively, an increased loss of \$3,058,506 or 334%. The loss was a result of a 50% interest in the following: Gross profit for 2004 was a negative \$4,339,000 compared with a negative \$17,600 for 2003, and increased loss of \$4,321,400. These losses were due mainly to the increased costs associated with the development of production in the new facility. As sales for 2004 increased to \$5,650,000 from \$1,133,675 for 2003, associated manufacturing costs increased to \$9,989,000 for 2004 from \$1,151,275 for 2003. Management expects the Joint Venture to be able to sell product at a gross profit. The expected increases in production efficiency received from the development of the Joint Venture with Tate & Lyle should offset pricing competition, but can provide no assurances in that regard to future increased production or future increased margin.

Selling, general and administrative expenses for the years ended 2004 and 2003 were \$3,440,000 and \$1,827,703, respectively an increase of \$1,612,297. These expenses are expected to remain at 2004 levels. The increase is due mainly to 2003 being a partial year for the venture. Interest expense increased to \$167,000 in 2004 from interest income of \$16,315 in 2003 as the venture incurs debt to finance its operation. The resulting losses were \$7,946,000 and \$1,828,988 for the years ended 2004 and 2003, respectively. For 2004, Igene's 50 % equity interest in the Joint venture loss was \$3,973,000. Igene's 50% equity interest in the Joint Venture loss was \$914,494 for 2003.

Because the Company accounts for its investment in the Joint Venture under the equity method of accounting, it would ordinarily recognize a loss representing its 50% equity interest in the loss of the Joint Venture. However, losses in the Joint Venture are recognized only to the extent of the Investment in and Advances to the Joint Venture. Losses in excess of this amount are suspended from recognition in the financial statements and carried forward to offset Igene's share of the Joint Venture's future income, if any.

Disposition of ProBio Subsidiary and net income from discontinued operations

As reported on Form 8-K on February 20, 2003, Igene, in an effort to focus on and grow its core business, disposed of all 10,000 of the issued and outstanding shares of the capital stock of ProBio. Fermtech AS, a joint stock company incorporated in the Kingdom of Norway and owned equally by our former chief executive officer, Stein Ulve and our former chief marketing officer, Per Benjaminsen, purchased the shares of ProBio. Mr. Ulve has resigned as CEO and director of Igene while Mr. Benjaminsen continues to serve the Company as an independent consultant, effective as of December 31, 2002.

Igene sold ProBio to Fermtech AS in exchange for aggregate consideration valued at approximately \$343,000, consisting of 7,000,000 shares of Igene common stock that Fermtech initially received in consideration for the purchase of ProBio in December 2001 (of these shares, 2,000,000 shares may be re-earned by Fermtech as described below), valued for the purposes of the acquisition at \$.03 per share, plus forgiveness of approximately \$168,000 of debt that Igene owed to ProBio at the time of purchase in 2001. By Mr. Benjaminsen remaining employed by Igene through February 2005, Fermtech re-earned all 2,000,000 of the escrowed shares. The remaining 5,000,000 shares of common stock of Igene were retired effective February 5, 2003. Gain on disposal during the year ended 2003 was \$237,637. This gain was a one-time occurrence as a result of the disposition of the assets and liabilities associated with ProBio.

The amount of consideration paid for ProBio was determined through arms-length negotiations between Igene management, on behalf of Igene, and Mr. Ulve, on behalf of Fermtech. Factors considered in determining the amount paid for the ProBio shares involved analysis of ProBio's cash flow, cash position, revenue and revenue prospects.

The equipment and other physical property owned by ProBio that was disposed of includes inventory, personal computers, a web site and trademark, other office equipment and furniture, and accounts receivable and accounts payable related to nutraceutical transactions.

Net loss and basic and diluted net loss per common share

As a result of the foregoing result of operations, Igene reported net losses of \$1,309,965 and \$2,170,893 for 2004 and 2003, respectively, a decreased loss of \$860,928 or 39%, a loss of \$.01 and \$.02 per basic and diluted common share in 2004 and 2003, respectively. The weighted average number of shares of common stock outstanding was 96,609,848 and 88,474,552 for 2004 and 2003, respectively, an increase of 8,135,296 shares. The increase in outstanding shares resulted from primarily the weighted average adjustment of the issuance of 2,950,000 shares in conversion of debentures issued in the purchase of ProBio, the issuance of 250,000 shares of common stock issued for legal service in the settlement of the ADM matter, the issuance of 3,640,792 shares to Igene's manufacturer under the manufacturing agreement with Fermic, 750,000 shares in issuance for exercise of employee stock incentive plan, 389,192 in conversion of redeemable preferred stock, 1,000,000 shares reissued to Fermtech as part of the disposition of ProBio.

Financial Position

During 2004 and 2003, the following also affected Igene's financial position:

- In April of 2004 the holder of Series B preferred stock, converted the 187,500 shares of preferred stock at a rate of two for one into 375,000 shares of common stock at a value of \$4.00 per share. The preferred shares were retired and the common shares issued. This relieved Igene of debt recorded at \$1,650,000 as of December 31, 2003.
- During 2004, decreases in accounts receivable and prepaid assets of \$161,474, and increases in accounts payable of \$654,769 were sources of cash.
- Igene sold to third parties or sold to the Joint Venture its entire inventory during 2003. The result was an increase to cash in 2003 of \$374,709.
- During 2004, \$190,255 used in advances to the Joint Venture, as compared with \$495,183 used in 2003.
- Increase in cash flow for 2003 has allowed for the reduction in accounts payable of \$409,784, in addition to which \$250,000 was used for the repayment of borrowings.
- During 2004, holders of Series A preferred stock converted 7,096 shares of preferred stock into 14,192 share of common stock, reducing the liquidation value of redeemable preferred stock by \$127,160. During 2003, 550 shares of preferred stock were converted into 1,100 shares of common stock, reducing the liquidation value of redeemable preferred stock by \$9,416.

- During 2004, \$295,000 of the \$1,000,000 of Convertible Debentures issued as part of the 2001 ProBio purchase, were converted to common stock. These shares were converted at \$.10 per share for a total of 2,950,000 shares. These shares were issued and the notes cancelled. This relieved the Company of \$295,000 of long-term debt.
- During the year ended December 31, 2003 3,750,000 warrants, were exercised using \$200,892 of 8% notes payable in a cashless exercise. 3,750,000 new shares of common stock were issued pursuant to these exercises of warrants and \$200,892 of 8% notes were cancelled.

Since December 1988, as part of an overall effort to contain costs and conserve working capital, Igene suspended payment of the quarterly dividend on its preferred stock. Resumption of the dividend will require significant improvements in cash flow. Unpaid dividends cumulate for future payment or addition to the liquidation preference or redemption value of the preferred stock. As of December 31, 2004, total dividends in arrears on Igene's preferred stock equal \$192,494 (or \$10.40 per share) and are included in the carrying value of the redeemable preferred stock.

Liquidity and Capital Resources

Historically, Igene has been funded primarily by equity contributions and loans from stockholders. As of December 31, 2004, Igene had a negative working capital of \$500,572, and cash and cash equivalents of \$204,248.

Cash provided by operating activities in 2004 was \$303,301 as compared to \$321,567 in 2003.

Cash used by investing activities in 2004 was 190,255 as compared to \$505,406 used by investing activities in 2003.

During 2004, cash provided by financing activities was \$28,127. During 2003 cash used by financing activities was \$250,797. It was comprised primarily of a \$250,000 repayment of notes received from directors during 2002.

Over the next twelve months, Igene believes it will need additional working capital. This funding is expected to be received from sales of AstaXin®, resulting in income from the Joint Venture. However, there can be no assurance that projected profits, if any, from sales, or additional funding from the Joint Venture will be sufficient for Igene to fund its continued operations.

Approximately \$5,800,000 in long-term debt was scheduled to become payable in March 2003, and has been extended to March 2006. We do not have the ability to repay such debt at this time and management feels any attempts to satisfy the debt at this time would have adverse effects on the Company. Management had negotiated with the holders of the debt to extend the debt's maturity to a time the Company felt it would be better able to satisfy its obligation. With seven months remaining until the extended maturity date, management is reviewing again extending this maturity date.

Igene does not believe that inflation had a significant impact on its operations during 2004 and 2003.

Critical Accounting Policies

The preparation of our financial statements in conformity with accounting principles generally accepted in the United States requires management to make judgments, assumptions and estimates that affect the amounts reported in our financial statements and accompanying notes. Actual results could differ materially from those estimates. The following are critical accounting policies important to our financial condition and results of operations presented in the financial statements and require management to make judgments and estimates that are inherently uncertain:

The Joint Venture's inventories are stated at the lower of cost or market. Cost is determined using a weighted-average approach, which approximates the first-in first-out method. If the cost of the inventories exceeds their expected market value, provisions are recorded for the difference between the cost and the market value. Inventories consist of currently marketed products.

The Joint Venture recognizes revenue from product sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed and determinable, and collectibility is reasonably assured. Allowances are established for estimated uncollectible amounts, product returns and discounts.

The Joint Venture has entered into a lease of real property with an affiliate of Tate & Lyle in Selby, England upon which a new manufacturing facility is being constructed and operated by the Joint Venture. The Joint Venture is accounted for under the equity method of accounting as the Company has a 50% ownership interest.

The Company can not recognize the loss of the Joint Venture beyond the investment in the Venture. This excess loss, and all future losses incurred as a result of the Joint Venture, that are in excess of the Company's investment and advances, will be suspended until the point that the profits of the Joint Venture, if any, exceed the incurred losses.

ITEM 7. CONSOLIDATED FINANCIAL STATEMENTS

The consolidated financial statements appear after Part III of this Report and are incorporated herein by reference.

ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS AND FINANCIAL DISCLOSURE

As of February 15, 2005, the Company dismissed its registered public accountant, Stegman & Company ("Stegman"), due to the Registrant's increased international audit requirements brought about by the Company's 50% participation in a joint venture with Tate & Lyle PLC (Tate & Lyle), which joint venture produces AstaXin(R) for the aquaculture industry at Tate & Lyle's Selby, England facility. The decision to dismiss Stegman was recommended by the Board of Directors of the Registrant during a meeting held on February 8, 2005. The audit reports issued by Stegman on the consolidated financial statements of the Registrant as of and for the years ended December 31, 2003, December 31, 2002 and prior, did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified, as to uncertainty, audit scope or accounting principles, except as follows:

Stegman's reports contain explanatory paragraphs. The paragraph states that the Company has suffered recurring losses from operations since inception and has a working capital deficiency that raises substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.

There have been no material disagreements between the Registrant and Stegman on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Stegman, would have caused Stegman to make reference to the subject matter thereof in its report on the Registrant's consolidated financial statements for such periods.

A letter from Stegman addressed to the Securities & Exchange Commission ("SEC") stating that Stegman agrees with the statements contained herein has been filed as an exhibit to this Form 10-KSB.

The Registrant has appointed Berenson LLP ("Berenson") as its new registered public accountants effective as of February 14, 2005. The selection of Berenson was approved by the Audit Committee of the Board of Directors of the Registrant on February 8, 2005.

ITEM 8A. CONTROLS AND PROCEDURES

Based on their most recent review, which was completed within 90 days of the balance sheet date, Igene's principal executive officer and principal financial officer have concluded that Igene's disclosure controls and procedures are effective to ensure that information required to be disclosed by Igene in the reports that it files or submits under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to Igene's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure and are effective to ensure that such information is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. There were no significant changes in Igene's internal controls or in other factors that could significantly affect those controls subsequent to the date of their evaluation.

The Company has restated its previously issued financial results for the second, third and fourth quarters of 2003, as well as the first three quarters of 2004. This restatement was primarily the result of the Company's investment in the Joint Venture which should have been recorded at an amount equal to the historical book value of the Company's consideration contributed at the creation of the Joint Venture (not its fair value). As a result, the investment in the Joint Venture should have been initially recorded with a value of \$316,860, rather than the \$12,300,000 initially recorded in the Financial Statements.

Additionally, the Company can not recognize the loss of the Joint Venture beyond its investment in the Venture. As of the fourth quarter of 2003, the Company had an initial investment of and amounts due from the Joint Venture of \$818,052. Igene's share of the loss through December 31, 2003 equaled \$914,494, exceeding the total investment by \$96,442. This excess loss, and all future losses incurred as a result of the Joint Venture, that are in excess of the Company's investment and advances, will be suspended until the point that the profits of the Joint Venture, if any, exceed the incurred losses.

The restatement also included the classification of the Company's preferred stock as liabilities in accordance with Statement of Financial Accounting Standards No. 150 "Accounting for certain Financial Instruments with Characteristics of both Liabilities and Equity" ("FASB 150"), which become effective in the third quarter of 2003. Amounts previously treated as dividends have been classified as interest expense.

PART III

ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS, CONTROL PERSONS, AND KEY EMPLOYEES

Igene's directors are elected annually by the stockholders of Igene. The directors, executive officers and key employees of Igene as of December 31, 2004 are as follows:

<u>Name</u>	<u>Age</u>	<u>Position with Igene</u>
Michael G. Kimelman	66	Chairman of the Board of Directors, member of audit committee
Thomas L. Kempner	77	Vice Chairman of the Board of Directors, member of finance committee
Stephen F. Hiu	48	Director, President, Chief Technical Officer, and Director of Research and Development
Patrick F. Monahan	54	Director, Vice-President, Secretary, and Director of Manufacturing
Sidney R. Knafel	74	Director, member of finance committee
Edward J. Weisberger	40	Chief Financial Officer
Per A. Benjaminsen	36	Director of Sales and Marketing

Each of our directors was elected for a one-year term at our most recent annual meeting, held in June of 2004. Our officers serve at the pleasure of the Board of Directors and until their respective successors are elected and qualified.

MICHAEL G. KIMELMAN has served as a Director of Igene since February 1991 and as Chairman of the Board of Directors since March 1991. He is a founder and member of Kimelman & Baird, LLC, as well as Chairman of the Board of Directors of Astaxanthin Partners Ltd. He also serves on the Board and the Executive Committee of the Hambletonian Society.

THOMAS L. KEMPNER is Vice Chairman of the Board of Directors and has been a Director of Igene since its inception in October 1981. He is and has been Chairman and Chief Executive Officer of Loeb Partners Corporation, investment bankers, New York, and its predecessors since February 1978. He is currently a Director of CCC Information Services Group, Inc., Dyax Corporation, Fuel Cell Energy, Inc., Insight Communications Co., Inc., and Intermagnetics General Corp and Intersections, Inc. He is a Director Emeritus of Northwest Airlines, Inc.

STEPHEN F. HIU was appointed Chief Technical Officer in 2002, and has served as President and Treasurer since March 1991, and elected a Director in August 1990. He has been Director of Research and Development since January 1989 and, prior thereto, was Senior Scientist since December 1985, when he joined Igene. He was a post-doctoral Research Associate at the Virginia Polytechnic Institute and State University, Blacksburg, Virginia, from January 1984 until December 1985. Dr. Hiu holds a Ph.D. degree in microbiology from Oregon State University and a B.S. degree in biological sciences from the University of California, Irvine.

PATRICK F. MONAHAN has served as Vice-President since 2002, and as Director of Manufacturing and as a Director of Igene since April 1991. He has served as Secretary since September 1998. He has managed Igene's fermentation pilot plant since 1982. He received an Associate of Arts degree in biology from Allegheny Community College and a B.S. degree in biology with a minor in Chemistry from Frostburg State College, Frostburg, Maryland.

SIDNEY R. KNAFEL, has served as a Director of Igene since 1982, has also been Managing Partner of SRK Management Company, a private investment concern located in New York City, since 1981. He has also served as Chairman of Insight Communications, Inc. since 1985. He is also currently a Director of General American Investors Company, Inc. as well as a number of private companies.

EDWARD J. WEISBERGER was appointed Chief Financial Officer of Igene in December 2001. He is a CPA with multiple years of financial experience in the public and private sectors with both smaller and fortune 100 companies.

PER A. BENJAMINSEN served as Chief Marketing Officer of Igene from December 2001 through December 2002. He received his degree in fisheries science at the University of Tromso, Norway. He was the founder and entrepreneur of a specialty refining company of essential fatty acids in Norway.

Section 16(a) Beneficial Ownership Reporting Compliance

Igene believes that during 2004 and through March of 2005 all of its officers and directors of more than 10% of its common stock, have filed all past due reports and come into compliance with Section 16(a) reporting requirements with respect to acquisitions and dispositions of Igene’s securities. In making this disclosure, Igene has relied solely on written representations of its directors, officers and more than 10% holders and on copies furnished to Igene of reports that have been filed with the Securities and Exchange Commission.

ITEM 10. EXECUTIVE COMPENSATION

The following tables show the compensation paid or accrued by Igene to each of the four most highly compensated officers. During 2004, no Directors were compensated for their Board or Committee activities. Other than the 1986, 1997 and 2001 Stock Incentive Plan and the Simple Retirement Plan described below, Igene has no profit sharing or incentive compensation plans.

SUMMARY COMPENSATION TABLE

Name and Principal Position	Year	Salary Compensation (\$)	Year	Salary Compensation (\$)
Stephen Hiu	2004	\$140,200	2003	\$113,400
President				
Patrick Monahan.....	2004	\$112,055	2003	\$103,506
Director				
Per Bejaminsen.....	2004	\$125,000	2003	\$100,000
Chief Marketing Officer				
Edward Weisberger	2004	\$109,605	2003	\$103,906
Chief Financial Officer				

Retirement Plans

Effective February 1, 1997 Igene adopted a Simple Retirement Plan under Internal Revenue Code Section 408(p). The plan was a defined contribution plan, which covered all of Igene’s U.S. employees who receive at least \$5,000 of compensation for the preceding year. The plan permits elective employee contributions. Effective January 1, 2003, Igene made an elective contribution of 3% of each eligible employee’s compensation for each year. Igene’s contributions to the plan for 2003 were \$17,631.

Effective February 1, 2004 Igene discontinued use of the Simple Retirement Plan and began use of a 401K plan. All employees that have been employed for three months are eligible for the plan. The plan permits elective contributions based under the Internal Revenue code. Effective January 1, 2004, Igene made an elective contribution of 4% of each eligible employee’s compensation for each year. Igene’s contributions to the plan for 2004 were \$19,221, which is expensed in the 2004 statement of operations.

Stock Option Plans

Igene currently maintains two stock incentive plans. Igene's 2001 Stock Incentive Plan (the "2001 Plan"), which was approved by Igene's stockholders on June 12, 2001, authorized 55,000,000 options and shares of restricted stock for issuance under that plan. Igene's 1997 Stock Option Plan (the "1997 Plan"), which was approved by Igene's stockholders on November 17, 1997, authorized 20,000,000 options for issuance under that plan. A committee of the Board of Directors administers the Plans.

The purpose of the Plans is to further the long-term stability and financial success of Igene by attracting and retaining employees and consultants through the use of stock-based incentives, and to provide non-employee members of the Board of Directors with an additional incentive to promote the success of Igene. It is believed that ownership of Igene common stock will stimulate the efforts of those employees, consultants and non-employee directors upon whose judgment and interests Igene is and will be largely dependent for the successful conduct of its business. It is also believed that incentive awards granted to employees under these plans will strengthen their desire to remain employed with Igene and will further the identification of employees' interests with those of Igene.

Options are exercisable at such rates and times as may be fixed by the committee. Options also become exercisable in full upon (i) the holder's retirement on or after his 65th birthday, (ii) the disability or death of the holder, or (iii) under other circumstances as determined by the Committee. Options generally terminate on the tenth business day following cessation of service as an employee, director, consultant or independent contractor.

Options may be exercised by payment in full of the option price in cash or check, or by delivery of previously-owned shares of common stock having a total fair market value on the date of exercise equal to the option price, or by such other methods as permitted by the Committee.

The Plans contain anti-dilution provisions in the event of certain corporate transactions.

The Board of Directors may at any time withdraw from, or amend, the Plans and any options not heretofore granted. Stockholder approval is required to (i) increase the number of shares issuable under the Plans, (ii) increase the number of options which may be granted to any individual during a year, (iii) or change the class of persons to whom options may be granted. No options shall be granted under the 2001 Plan after April 30, 2011 and under the 1997 Plan after September 19, 2007. Igene previously maintained its 1986 Stock Option Plan, but additional options may no longer be granted under that plan.

Options to acquire 47,973,250 shares of common stock have been granted under the three Stock Option Plans and 46,927,750 options are still outstanding under the Plans as of December 31, 2004. 11,989,500 were granted during 2004 and no options were granted during 2003.

Compensation of Directors

During 2003 Michael G. Kimelman was granted 11,000,000 warrants as compensation for his services as Igene's Chairman of the Board of Directors.

ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following table sets forth information as of August 25, 2005 with respect to beneficial ownership of shares of Igene's outstanding common stock and preferred stock by (i) each person known to Igene to own or beneficially own more than five percent of its common stock or preferred stock, (ii) each Director, and (iii) each officer named in the Summary Compensation Table provided in Part II Item 10 above, and (iv) all Directors and executive officers as a group.

<u>Name and Address</u>	<u>Common Stock</u>		<u>Preferred Stock</u>	
	<u>Number of Shares</u>	<u>Percent *</u>	<u>Number of Shares</u>	<u>Percent</u>
<u>Directors and officers</u>				
Joseph C. Abeles 220 E. 42nd Street New York, NY 10017	16,273,483 ¹	14.04	7,375	39.84
Stephen F. Hiu 9110 Red Branch Road Columbia, MD 21045	15,948,633 ²	13.69	---	---
Thomas L. Kempner 61 Broadway New York, NY 10006	143,139,072 ³	63.12	---	---
Michael G. Kimelman 100 Park Avenue New York, NY 10017	33,590,138 ⁴	25.06	---	---
Sidney R. Knafel 810 Seventh Avenue New York, NY 10019	141,326,146 ⁵	62.85	---	---
Patrick F. Monahan 9110 Red Branch Road Columbia, MD 21045	8,947,533 ⁶	8.16	---	---
Per A. Benjaminsen 9110 Red Branch Road Columbia, MD 21045	11,000,000 ⁷	9.84	---	---
Edward J. Weisberger 9110 Red Branch Road Columbia, MD 21045	3,070,000 ⁸	2.93	---	---
All Directors and Officers as a Group (8 persons)	371,148,442 ⁹	86.25	7,375	39.84
<u>Others</u>				
Fraydun Manocherian 3 New York Plaza New York, NY 10004	7,905,135 ¹⁰	7.73	---	---
Fermic	14,730,014	14.48	---	---

* Under the rules of the Securities and Exchange Commission, the calculation of the percentage assumes for each person that only that person's rights, warrants, options or convertible notes or preferred stock are exercised or converted, and that no other person exercises or converts outstanding rights, warrants, options or convertible notes or preferred stock.

1. Includes the following: 2,113,544 shares held directly or indirectly by Mr. Abeles, 14,750 shares issuable upon the conversion of 7,375 shares of preferred stock, 5,042,777 shares issuable upon the conversion of \$311,663 of long-term notes issued by Igene, and 9,102,412 shares issuable upon exercise of warrants held by Mr. Abeles.
2. Includes the following: 1,148,633 shares held directly or indirectly by Mr. Hiu and 14,800,000 shares issuable pursuant to options held by Dr. Hiu that are currently exercisable.
3. Includes 386,972 shares and 536,920 shares issuable upon exercise of warrants held by Mr. Kempner that are currently exercisable. Also includes 8,661,245 shares held directly by Mr. Kempner, 18,761,668 shares issuable upon conversion of notes issued by Igene and held by Mr. Kempner, and 41,582,728 shares issuable upon exercise of warrants held by a trust under which Mr. Kempner is one of two trustees and the sole beneficiary, which are currently exercisable. Also includes 8,621,247 shares held directly by Mr. Kempner, 18,761,669 shares issuable upon the conversion of notes issued by Igene and held by Mr. Kempner and 41,561,125 shares issuable upon exercise of warrants held a trust under which Mr. Kempner is one of two trustees and one of his brothers is the sole beneficiary, which are currently exercisable. Also includes 1,530,222 shares issuable upon the conversion of \$79,200 of notes issued by Igene and held by Mr. Kempner and 2,079,411 shares issuable upon exercise of warrants held by trusts under which Mr. Kempner is one of two trustees and is a one-third beneficiary that are currently exercisable. Also includes 243,360 shares and 131,414 shares issuable upon exercise of warrants held by trusts under which Mr. Kempner is executor and is a one-third beneficiary that are currently exercisable. Also includes 182,526 shares and 98,565 warrants held by Mr. Kempner's wife.
4. Includes 1,264,360 shares held directly or indirectly by Mr. Kimelman, 14,000,000 shares issuable upon exercise of options currently exercisable, 1,072,756 shares issuable upon the conversion of \$63,070 of notes issued by Igene and held by Mr. Kimelman, and 17,253,022 shares issuable upon exercise of warrants held directly or indirectly by Mr. Kimelman.
5. Includes 18,190,551 shares, 38,168,101 shares issuable upon the conversion of notes issued by Igene and held by Mr. Knafel and 84,967,495 shares issuable upon the exercise of warrants owned or beneficially owned by Mr. Knafel that are currently exercisable.
6. Includes 1,047,533 shares held directly or indirectly by Mr. Monahan and 7,900,000 shares issuable upon the exercise of options held by Mr. Monahan that are currently exercisable.
7. Includes 1,000,000 shares of common stock and 10,000,000 shares issuable upon exercise of options held by Mr. Benjaminsen that are currently exercisable.
8. Includes 70,000 shares held directly by Mr. Weisberger and 3,000,000 shares issuable upon exercise of options that are currently exercisable.
9. Includes 42,576,099 shares of common stock, 14,750 shares issuable upon the conversion of 7,375 shares of preferred stock; 49,667,250 shares issuable upon exercise of options that are currently exercisable, 82,680,765 shares issuable upon the conversion of notes issued by Igene and 196,209,578 shares issuable upon the exercise of warrants that are currently exercisable.
10. Includes 7,375,935 shares of common stock owned directly or indirectly by Mr. Manocherian and 529,200 shares issuable upon the exercise of warrants owned directly or indirectly by Mr. Manocherian that are currently exercisable.

Equity Compensation Plan Information as of December 31, 2004

Plan category	Number of securities to be issued upon exercise of outstanding options, warrants and rights	Weighted-average exercise price of outstanding options, warrants and rights	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column)
Equity compensation plans approved by security holders	46.9 million (1)	\$0.06.1 (2)	27.026 million (3)
Equity compensation plans not approved by security holders	\$ 0	\$ 0	5.269 million (4)
Total	46.9 million	\$0.061	32.295 million

(1)	Total shares issued under employee stock option plan.
(2)	Exercise price of outstanding options under compensation plans.
(3)	All shares remaining issuable under employee option plan.
(4)	All shares remaining earnable under the Fermic manufacturing agreement.

Fermic, Igene's manufacturing agent, earns shares of common stock as part of the manufacturing agreement. Fermic earns 2,250 shares of common stock for each kilogram of pure astaxanthin produced and delivered as part of the agreement. The average price is based on the market value of the shares at the time the product was produced. Fermic can earn up to 20,000,000 shares in total under the contract. 3,640,792 shares were earned at an average price of \$.11 per share for 2004, and 2,785,957 shares were earned at an average price of \$.05 per share for 2003.

ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.

On April 3, 2003, the Board of Directors, in lieu of additional compensation, authorized the payment of shares to Mr. Stephen Hiu and Mr. Patrick Monahan. In compensation each of them was awarded 83,333 shares of Igene common stock. The aggregate 166,666 shares was issued and expensed based on market value at the time of award, \$.060 per share, or \$10,000 of combined compensation.

As reported on Form 8-K filed February 20, 2003, Igene, in an effort to focus on and grow its core business, sold all 10,000 of the issued and outstanding shares of capital stock of ProBio that it owned as of February 4, 2003 to Fermtech AS, a joint stock company incorporated in the Kingdom of Norway and owned equally by our former chief executive officer, Stein Ulve, and by Per Benjaminsen, our Chief Marketing Officer. Mr. Ulve resigned as CEO and director of Igene and Mr. Benjaminsen resigned as our chief marketing officer, effective December 31, 2002. Mr. Benjaminsen has agreed to continue to provide sales and marketing services to Igene as an independent contractor.

Igene sold ProBio to Fermtech AS in exchange for aggregate consideration valued at approximately \$343,000, a portion of the consideration received by Igene consisted of 7,000,000 shares of common stock of Igene that Fermtech owned as a result of Igene's purchase of ProBio in January 2001, (of these shares, 2,000,000 shares have been re-earned by Fermtech as described below), valued for the purposes of the acquisition at \$.03 per share, plus forgiveness of approximately \$168,000 of debt that Igene owed to ProBio at the time of purchase in 2001. By Mr. Benjaminsen remaining employed by Igene through February 2005, all 2,000,000 of the escrowed shares of common stock were delivered to Fermtech. The remaining shares of Igene common stock were retired on February 5, 2003.

ITEM 13. EXHIBITS, FINANCIAL STATEMENTS, SCHEDULES, AND REPORTS ON FORM 8-K

(a)(1) The following financial statements relating to 2004 and 2003 are filed as a part of this Report:

Reports of Independent Registered Public Accounting Firm.

Consolidated Balance Sheet as of December 31, 2004.

Consolidated Statements of Operations for the years ended December 31, 2004 and 2003.

Consolidated Statements of Stockholders' Deficiency for the years ended December 31, 2004 and 2003.

Consolidated Statements of Cash Flows for the years ended December 31, 2004 and 2003.

Notes to Consolidated Financial Statements.

(a)(2) Exhibits filed herewith or incorporated by reference herein are set forth in the following table prepared in accordance with Item 601 of Regulations S-K.

- 3.1 Articles of Incorporation of the Registrant as amended to date, constituting Exhibit 3.1 to Registration Statement No. 333-41581 on Form SB-1 are hereby incorporated herein by reference.
- 3.2 By-Laws, constituting Exhibit 3.2 to the Registrant's Registration Statement No. 33-5441 on Form S-1, are hereby incorporated herein by reference.
- 4.1 Form of Variable Rate Convertible Subordinated Debenture Due 2002 (Class A), constituting Exhibit 4.4 to Registration Statement No. 33-5441 on Form S-1, is hereby incorporated herein by reference.
- 10.1 Form of Conversion and Exchange Agreement used in May 1988 in connection with the conversion and exchange by certain holders of shares of preferred stock for common stock and Warrants, constituting Exhibit 10.19 to Registration Statement No. 33-5441 on Form S-1, is hereby incorporated herein by reference.
- 10.2 Exchange Agreement made as of July 1, 1988 between the Registrant and now Dow Chemical Company, Inc. (f.k.a. Essex Industrial Chemicals, Inc.), with respect to the exchange of 187,500 shares of preferred stock for a Debenture, constituting Exhibit 10.21 to Registration Statement No. 33-5441 on Form S-1, is hereby incorporated herein by reference.
- 10.3 Preferred Stockholders' Waiver Agreement dated May 5, 1988, incorporated herein by reference to the identically numbered exhibit in Form S-1 Registration Statement No. 33-23266.
- 10.4 Form of Agreement between the Registrant and Certain Investors in preferred stock dated September 30, 1987, incorporated herein by reference to the identically numbered exhibit in Amendment No. 1 to Form S-1 Registration Statement No. 33-23266.
- 10.5 Letter Agreement executed May 11, 1995 between Archer Daniels Midland, Inc. and IGENE Biotechnology, Inc., along with November 11, 1995 Amendment, constituting Exhibit 10.11 to the Registrant's Report on Form 10-KSB for the year ended December 31, 1995 is incorporated herein by reference.
- 10.6 Agreement of Lease effected December 15, 1995 between Columbia Warehouse Limited Partnership and IGENE Biotechnology, Inc. constituting Exhibit 10.13 to the registrant's report on Form 10-KSB for the year ended December 31, 1995 is incorporated herein by reference.
- 10.7 Toll manufacturing agreement effective as of May 20, 2000 between Igene Biotechnology, Inc. and Fermic S.A. de C.V. constituting exhibit 10.7 to Igene's annual report on Form 10-KSB filed on April 2, 2001, is incorporated herein by reference. Portions of this exhibit have been omitted pursuant to a request for confidential treatment.

- 10.8 First amendment to lease made September 13, 2000 between Igene Biotechnology, Inc. and Red Branch Center, LLC constituting Exhibit 10.8 to Igene's annual report on Form 10-KSB filed on April 2, 2001, is incorporated herein by reference.
- 10.9 Consulting Agreement between Igene and Martin L. Gerson, Exhibit 10.9 to Igene's annual report on Form 10-KSB filed on March 28, 2003, is incorporated herein by reference.
- 10.10 Stock Purchase and Severance Agreement dated as of the 4th day of February 2003 among Igene, Fermtech AS, Stein Ulve and Per Benjaminsen, constituting Exhibit 10.10 to Igene's annual report on Form 10-KSB filed on March 28, 2003, is incorporated herein by reference.
- 21. Subsidiaries
 - Igene Chile Comercial, Ltda.
 - Igene Norway AS (divested pursuant to Stock Purchase and Severance Agreement dated February 4, 2003 attached hereto as Exhibit 10.10)
- 23.a. Consent of Berenson LLP
- 23.b. Consent of Stegman & Company
- 31.1 Rule 13a-14(a) or 15d-14(a) Certification of the Company's principal executive officer filed herewith.
- 31.2 Rule 13a-14(a) or 15d-14(a) Certification of the Company's principal financial officer filed herewith.
- 32.1 Rule 13a-14(b) or 15d-14(b) Certification of the Company's principal executive officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Rule 906 of the Sarbanes-Oxley Act of 2002 filed herewith.
- 32.2 Rule 13a-14(b) or 15d-14(b) Certification of the Company's principal financial officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Rule 906 of the Sarbanes-Oxley Act of 2002 filed herewith.

ITEM 14. PRINCIPAL ACCOUNTANTS FEES AND SERVICES

REGISTERED PUBLIC ACCOUNTANTS

The accounting firm of Berenson LLP, Certified Public Accountants, has been engaged to audit the books and accounts of the Company for the next fiscal year. Berenson LLP serviced as the Company's registered public auditor in 2004. Berenson LLP has advised the Company that neither the accounting firm nor any of its members of associates has any direct financial interest in or any connection with the Company other than as independent public auditors.

AUDIT FEES AND SERVICES

The following table shows the fees paid by the Company for the audit and other services provided by Stegman & Company for fiscal years 2004 and 2003:

	FY 2004	FY 2003
	-----	-----
Audit Fees	\$ 30,924.00	\$ 25,750.00
Tax Fees	3,000.00	2,500.00
All Other Fees	0.00	0.00
	-----	-----
TOTAL	\$ 33,924.00	\$ 28,250.00

Audit services of Stegman & Company for fiscal years 2004 and 2003 consisted of the examination of the consolidated financial statements of the Company and quarterly reviews of financial statements. "Tax Fees" in fiscal years 2004 and 2003 include charges primarily related to tax return preparation and tax consulting services. In 2003, the SEC adopted a rule pursuant to the Federal Sarbanes-Oxley Act of 2002 that, except with respect to certain *de minimis* services discussed below, requires Audit Committee pre-approval of audit and non-audit services provided by the Company's independent auditors. All of the 2004 services described above were pre-approved by the Audit Committee pursuant to this SEC rule to the extent that rule was applicable during fiscal year 2004.

The Audit Committee's policy is to pre-approve all audit and permitted non-audit services, except that *de minimis* non-audit services, as defined in Section 10A(i)(1) of the Exchange Act, may be approved prior to the completion of the independent auditor's audit. The Audit Committee has reviewed summaries of the services provided and the related fees and has determined that the provision of non-audit services is compatible with maintaining the independence of Stegman & Company.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS

To the Audit Committee and Stockholders
IGENE Biotechnology, Inc.

We have audited the accompanying consolidated balance sheet of IGENE Biotechnology, Inc. and subsidiary as of December 31, 2004, and the related consolidated statements of operations, stockholders' deficiency and cash flows for the year then ended. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of IGENE Biotechnology, Inc. and subsidiary as of December 31, 2004, and the results of their operations and their cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 13 to the consolidated financial statements, the Company's recurring losses, production limitations and limited capitalization raise substantial doubt about its ability to continue as a going concern. Management's plans regarding those matters also are described in Note 13. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ BERENSON LLP

BERENSON LLP

New York, New York
March 25, 2005

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Audit Committee and Stockholders
IGENE Biotechnology, Inc.

We have audited the accompanying consolidated statements of operations, stockholders' deficit and cash flows of IGENE Biotechnology, Inc. and Subsidiary (the "Company") for the year ended December 31, 2003. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the results of operations and cash flows of the Company for the year ended December 31, 2003, in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 13 to the consolidated financial statements, the Company's recurring losses, production limitations and limited capitalization raise substantial doubt about its ability to continue as a going concern. Management's plans regarding those matters also are described in Note 13. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ STEGMAN & COMPANY

STEGMAN & COMPANY

Baltimore, Maryland
August 18, 2005

IGENE Biotechnology, Inc. and Subsidiary
Consolidated Balance Sheet
December 31, 2004

ASSETS

CURRENT ASSETS

Cash and cash equivalents	\$ 204,248
Accounts receivable	79,638
Prepaid expenses and other current assets	<u>10,764</u>
TOTAL CURRENT ASSETS	294,650

Property and equipment, net	124,904
Loan receivable from manufacturing agent	70,982
Investment in and advances to unconsolidated joint venture	---
Other assets	<u>5,125</u>
TOTAL ASSETS	<u>\$ 495,661</u>

LIABILITIES AND STOCKHOLDERS' DEFICIENCY

CURRENT LIABILITIES

Accounts payable and accrued expenses	\$ 78,472
Convertible debenture	705,000
Accrued interest	<u>11,750</u>
TOTAL CURRENT LIABILITIES	795,222

LONG-TERM DEBT

Notes payable	5,842,267
Convertible Debentures	3,814,212
Accrued interest	4,148,681

REDEEMABLE PREFERRED STOCK

Carrying amount of redeemable preferred stock, 8% cumulative, convertible, voting, series A, \$.01 par value per share. Stated value \$18.40 per share. Authorized 1,312,500 shares; issued and outstanding 18,509 shares. Redemption amount \$340,566.	<u>340,566</u>
TOTAL LIABILITIES	<u>14,940,948</u>

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' DEFICIENCY

Common stock -- \$.01 par value per share. Authorized 750,000,000 shares; issued and outstanding 101,732,453 shares	1,017,325
Additional paid-in capital	25,138,748
Accumulated Deficit	<u>(40,601,360)</u>
TOTAL STOCKHOLDERS' DEFICIENCY	<u>(14,445,287)</u>

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	<u>\$ 495,661</u>
--	-------------------

The accompanying notes are an integral part of the consolidated financial statements.

IGENE Biotechnology, Inc. and Subsidiary
Consolidated Statements of Operations

	Years ended December 31,	
	2004	2003
<u>REVENUE</u>		
Sales	\$ ---	\$ 463,486
Cost of sales	---	446,144
 GROSS PROFIT	 ---	 17,342
 EQUITY IN LOSS OF JOINT VENTURE	 (190,255)	 (818,052)
<u>OPERATING EXPENSES</u>		
Marketing and selling	326,689	328,393
Research, development and pilot plant	847,544	745,364
General and administrative	688,125	687,427
Litigation expenses	40,580	133,464
Less expenses reimbursed by Joint Venture	(1,612,845)	(1,252,565)
 TOTAL OPERATING EXPENSES	 290,093	 642,083
 OPERATING LOSS	 (480,348)	 (1,442,793)
 INTEREST EXPENSE	 (829,617)	 (965,737)
 NET LOSS FROM CONTINUING OPERATIONS	 (1,309,965)	 (2,408,530)
 Gain on disposal of discontinued operations	 ---	 237,637
 NET LOSS	 \$ (1,309,965)	 \$ (2,170,893)
 BASIC AND DILUTED NET LOSS PER COMMON SHARE FROM CONTINUING OPERATIONS	 \$ (0.01)	 \$ (0.02)
 BASIC AND DILUTED NET INCOME PER COMMON SHARE FROM DISCONTINUED OPERATIONS	 0.00	 0.00
 BASIC AND DILUTED NET LOSS PER COMMON SHARE	 \$ (0.01)	 \$ (0.02)

The accompanying notes are an integral part of the consolidated financial statements.

IGENE Biotechnology, Inc. and Subsidiary
Consolidated Statements of Stockholders' Deficiency
For The years ended December 31, 2004 and 2003

	Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Deficiency
	# Shares	Amount			
BALANCE AT JANUARY 1, 2003	92,943,746	\$ 929,437	\$ 22,387,604	\$ (37,120,502)	\$ (13,803,461)
Retirement of common stock related to sale of ProBio	(7,000,000)	(70,000)	(140,000)	---	(210,000)
Cumulative undeclared dividends on redeemable preferred stock	---	---	(98,193)	---	(98,193)
Conversion of redeemable preferred stock into common stock	1,100	11	9,405	---	9,416
Exercise of warrants	3,750,000	37,500	243,750	---	281,250
Shares issued to S. Hiu and P. Monahan in lieu of compensation	166,666	1,667	8,333	---	10,000
Shares issued for employee stock incentive program	100,000	1,000	1,500	---	2,500
Shares issued for manufacturing agreement	2,785,957	27,860	144,154	---	172,014
Net loss for 2003	---	---	---	(2,170,893)	(2,170,893)
BALANCE AT DECEMBER 31, 2003	92,747,469	927,475	22,556,553	(39,291,395)	(15,807,367)
Conversion of redeemable preferred stock into common stock	389,192	3,892	1,803,268	---	1,807,160
Shares issued to attorney in settlement of ADM matter	250,000	2,500	25,000	---	27,500
Conversion of 8% Notes	5,000	50	325	---	375
Re-issuance or shares held in escrow related to sale of ProBio	1,000,000	10,000	100,000	---	110,000
Conversion of debentures issued as part of ProBio purchase	2,950,000	29,500	265,500	---	295,000
Shares issued for employee stock incentive program	750,000	7,500	22,250	---	29,750
Shares issued for manufacturing agreement	3,640,792	36,408	365,852	---	402,260
Net loss for 2004	---	---	---	(1,309,965)	(1,309,965)
BALANCE AT DECEMBER 31, 2004	<u>101,732,453</u>	<u>\$ 1,017,325</u>	<u>\$ 25,138,748</u>	<u>\$ (40,601,360)</u>	<u>\$ (14,445,287)</u>

The accompanying notes are an integral part of the consolidated financial statements.

**IGENE Biotechnology, Inc. and Subsidiary
Consolidated Statements of Cash Flows**

	Years ended December 31, 2004	2003
<u>CASH FLOWS FROM OPERATING ACTIVITIES</u>		
Net loss	\$ (1,309,965)	\$ (2,170,893)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Depreciation	24,027	29,057
Amortization of deferred costs	---	54,729
Gain on disposal of discontinued operations	---	(237,637)
Compensation paid in shares of common stock	---	10,000
Issuance of shares to Fermtech per ProBio agreement	110,000	---
Issuance of common stock for legal service	27,500	---
Manufacturing cost paid in shares of common stock	402,260	172,014
Increase in preferred stock for cumulative dividend classified as interest	42,981	68,194
Equity in loss of unconsolidated joint venture	190,255	818,052
Decrease (increase) in:		
Accounts receivable	76,820	359,059
Inventory	---	374,709
Prepaid expenses and other assets	84,654	1,254,067
Increase (decrease) in:		
Accounts payable and other accrued expenses	654,769	(409,784)
	303,301	321,567
NET CASH PROVIDED BY OPERATING ACTIVITIES		
<u>CASH FLOWS FROM INVESTING ACTIVITIES</u>		
Cash transferred to Joint Venture	---	(4,223)
Advances to Joint Venture	(190,255)	(495,183)
Investment in Joint Venture Capital Stock	---	(6,000)
NET CASH USED IN INVESTING ACTIVITIES	(190,255)	(505,406)
<u>CASH FLOWS FROM FINANCING ACTIVITIES</u>		
Repayment of equipment lease payable	(1,498)	(3,297)
Proceeds from exercise of employee stock options	29,750	2,500
Repayment of borrowing	(125)	(250,000)
NET CASH PROVIDED (USED) BY FINANCING ACTIVITIES	28,127	(250,797)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	141,173	(434,636)
CASH AND CASH EQUIVALENTS - BEGINNING OF THE YEAR	63,075	497,711
CASH AND CASH EQUIVALENTS - END OF THE YEAR	\$ 204,248	\$ 63,075
<u>SUPPLEMENTARY DISCLOSURE AND CASH FLOW INFORMATION</u>		
Cash paid during the year for interest	\$ 24,480	\$ 61,171
Cash paid during the year for income taxes	---	---

The accompanying notes are an integral part of the consolidated financial statements.

IGENE Biotechnology, Inc. and Subsidiary
Notes to Consolidated Financial Statements
For the years ended December 31, 2004 and 2003

(1) **Summary of Significant Accounting Policies**

Nature of Operations

Igene Biotechnology, Inc. ("Igene") was incorporated under the laws of the State of Maryland on October 27, 1981 as "Industrial Genetics, Inc." Igene changed its name to "IGI Biotechnology, Inc." on August 17, 1983 and to "Igene Biotechnology, Inc." on April 14, 1986. Igene is located in Columbia, Maryland and is engaged in the business of industrial microbiology and related biotechnologies. Igene has an operational subsidiary in Chile and through February 2003 had a subsidiary in Norway. IGENE Biotechnology, Inc. is engaged in the business of developing, marketing, and manufacturing specialty ingredients for human and animal nutrition. Igene was formed to develop, produce and market value-added specialty biochemical products. Igene is a supplier of natural astaxanthin, an essential nutrient in different feed applications and as a source of pigment for coloring farmed salmon species. Igene also supplies nutraceutical ingredients, as well as consumer ready health food supplements, including astaxanthin. Igene is focused on fermentation technology, pharmacology, nutrition and health in its marketing of products and applications worldwide.

Igene has devoted its resources to the development of proprietary processes to convert selected agricultural raw materials or feedstocks into commercially useful and cost effective products for the food, feed, flavor and agrochemical industries. In developing these processes and products, Igene has relied on the expertise and skills of its in-house scientific staff and, for special projects, various consultants.

In an effort to develop a dependable source of production, on March 18, 2003, Tate and Lyle and Igene announced a 50:50 joint venture to produce AstaXin® for the aquaculture industry. Production will utilize Tate & Lyle's fermentation capability together with the unique technology developed by Igene. Part of Tate & Lyle's existing Selby, England, citric acid facility will be modified to include the production of 1,500 tons per annum of this product. Tate & Lyle's investment of \$25 million includes certain of its facility assets currently used in citric acid production.

Principles of Consolidation

In December 2001 Igene purchased its sales agent ProBio Nutraceuticals, AS, a Norwegian corporation ("ProBio"). During 2003, Igene executed a formal agreement to dispose of ProBio. For the 2002 consolidated financial statements, the earnings and losses had been treated as loss from discontinued operations. The accounts of our other wholly-owned subsidiary, Igene Chile are included in the consolidation of these financial statements. All significant intercompany accounts and transactions have been eliminated in consolidation.

Cash and cash equivalents

Igene considers cash equivalents to be short-term, highly liquid investments that have original maturities of less than 90 days. These include interest bearing money market accounts.

Accounts Receivable

Accounts receivable are stated at the amount management expects to collect from the outstanding balances. Management provides for probable uncollectible amounts through a charge to earnings and a credit to a valuation allowance based upon its assessment of the current collection status of individual accounts. Delinquent amounts that are outstanding after management has conducted reasonable collection efforts, are written off through a charge to the valuation allowance and a credit to accounts receivable. The valuation allowance did not change in the current period.

IGENE Biotechnology, Inc. and Subsidiary
Notes to Consolidated Financial Statements
For the years ended December 31, 2004 and 2003

Investment in and advances to unconsolidated joint venture

The investment in the Joint Venture is accounted for under the equity method whereby the Company's 50% ownership percentage in the Joint Venture is reflected as an asset in the consolidated balance sheet and the changes in the Joint Venture's equity as a result of its operations is reflected in the Company's consolidated statement of operations. The Company evaluates its investment in the Joint Venture for impairment, as it does for all long term assets. The Company can not recognize the loss of the Joint Venture beyond its investment in the Venture. This excess loss, and all future losses incurred as a result of the Joint Venture, that are in excess of the Company's investment and advances, are suspended until the point that the profits of the Joint Venture, if any, exceed the incurred losses. The accounting policies followed by the Joint Venture are in conformity with accounting principles generally accepted in the United States of America.

Research and development costs

For financial reporting purposes, research, development and pilot plant scale-up costs are charged to expense as incurred.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization computed using the straight-line method. Premises and equipment are depreciated over the useful lives of the assets, which generally range from three to ten years for furniture, fixtures and equipment, three to five years for computer software and hardware. Leasehold improvements are amortized over the terms of the respective leases or the estimated useful lives of the improvements, whichever is shorter. The cost of major renewals and betterments are capitalized, while the costs of ordinary maintenance and repairs are expensed as incurred.

Estimates

The preparation of financial statements in conformity with accounting principles generally acceptable in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Foreign Currency Translation and Transactions

Since the day-to-day operations of Igene's foreign subsidiary in Chile are dependent on the economic environment of the parent's currency, the financial position and results of operations of Igene's foreign subsidiary are determined using Igene's reporting currency (US dollars) as the functional currency. All exchange gains and losses from remeasurement of monetary assets and liabilities that are not denominated in US dollars are recognized currently in income. The gains are due to large fluctuations in the Chilean Peso.

Fair value of financial instruments

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and short-term debt approximate fair value because of the relatively short maturity of these instruments. Management believes the carrying amount of long-term debt approximates fair value because of similar current rates at which Igene could borrow funds with consistent remaining maturities.

IGENE Biotechnology, Inc. and Subsidiary
Notes to Consolidated Financial Statements
For the years ended December 31, 2004 and 2003

Accounting for stock based compensation

The Company has adopted the disclosure-only provisions of Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based Compensation" (SFAS No. 123), and SFAS No. 148, "Accounting for Stock-Based Compensation-Transition and Disclosure", but applies Accounting Principals Board Opinion No. 25 and related interpretations in accounting for its stock option plans. No compensation expense related to the Company's stock option plans were recorded during the two years ended December 31, 2004.

The Company accounts for those plans under the recognition and measurement principles of APB Opinion No. 25, "Accounting for Stock Issued to Employees", and related interpretations. No stock option based employee compensation cost is reflected in net loss, as all options granted under the plan had an exercise price equal to the market value of the underlying common stock on the date of grant. The following table illustrates the effect on net loss and earnings per share if the Company had applied the fair value recognition provisions of SFAS No. 123, "Accounting for Stock-Based Compensation" and disclosure provisions of SFAS No. 148 "Accounting for Stock-Based Compensation-Transition and Disclosure", to stock-based employee compensation for the two years ended December 31:

	2004	2003
Net loss, as reported	\$ (1,309,965)	\$ (2,170,893)
Pro forma stock-based employee compensation expense determined under fair value based method net of related tax effects	(1,174,213)	(529,000)
Pro forma net loss	\$ (2,484,178)	\$ (2,699,893)
Net loss per Share:		
Basic – as reported	\$ (0.01)	\$ (0.02)
Basic – pro forma	\$ (0.03)	\$ (0.03)
Diluted – as reported	\$ (0.01)	\$ (0.02)
Diluted – pro forma	\$ (0.03)	\$ (0.03)

The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions used for grants during the two years ended December 31:

	2004	2003
Dividend yield	---	---
Expected volatility	144.90%	51.79%
Risk-free interest rate	4.63%	4.21%
Expected lives in years	10	10
Fair value of options granted	\$0.10	\$0.04

New accounting pronouncements

In November 2004, the FASB issued SFAS No. 151, "Inventory Costs, an amendment of ARB No.43, Chapter 4." SFAS amends Accounting Research Bulletin ("ARB") No.43, Chapter 4, to clarify that abnormal amounts of idle facility expense, freight, handling costs and wasted materials (spoilage) should be recognized as current-period charges. In addition, SFAS No.151 requires that allocation of fixed production overhead to inventory be based on the normal capacity of the production facilities. SFAS No.151 is effective for inventory costs incurred during the fiscal years beginning after June 15, 2005. The Company is currently assessing the impact SFAS No.151 will have on the results of operations, financial position or cash flows.

IGENE Biotechnology, Inc. and Subsidiary
Notes to Consolidated Financial Statements
For the years ended December 31, 2004 and 2003

In April 2003, the Financial Accounting Standards Board (“FASB”) issued Statement of Financial Accounting Standards (“SFAS”) No. 149, “Amendment of Statement 133 on Derivative Instruments and Hedging Activities”. SFAS No. 149 amends and clarifies financial accounting and reporting for derivative instruments, including certain derivative instruments embedded in other contracts, and for hedging activities under SFAS No. 133, “Accounting for Derivative Instruments and Hedging Activities”. The Statement is effective for contracts entered into or modified after June 30, 2003 and for hedging relationships designated after June 30, 2003. There was no material impact on the Company’s financial condition or results of operations upon adoption of this Statement.

In May 2003, the FASB issued SFAS No. 150, “Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity”. SFAS No. 150 establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both a liability and equity. It requires that an issuer classify certain financial instruments as a liability, although the financial instrument may previously have been classified as equity. This Statement is effective for financial instruments entered into or modified after May 31, 2003 and otherwise is effective at the beginning of the first interim period beginning after June 15, 2003. The effect of adopting this pronouncement required the reclassification of \$2.04 million of redeemable preferred stock as a liability.

In January 2003, the FASB issued Interpretation No. 46, “Consolidation of Variable Interest Entities” (“FIN 46”), which explains identification of variable interest entities and the assessment of whether to consolidate these entities. FIN 46 requires existing unconsolidated variable interest entities to be consolidated by their primary beneficiaries if the entities do not effectively disperse risks among the involved parties. The provisions of FIN 46 are effective for all financial statements issued after January 1, 2003. The Company has no significant variable interests in any entities which would require disclosure or consolidation. The Company’s investment in the Joint Venture does not meet the criteria of a variable interest entity under FIN 46.

(2) Non-cash investing and financing activities:

On March 18, 2003, the Company entered into a Joint Venture Agreement with Tate & Lyle Fermentation Products Ltd. (“Tate”). Pursuant to a Joint Venture Agreement, the Company and Tate agreed to form a joint venture (the “Joint Venture”) to manufacture, market and sell Astaxanthin and derivative products throughout the world for all uses other than as a Nutraceutical or otherwise for direct human consumption. Tate contributed \$24,600,000 in cash to the Joint Venture, while the Company contributed to the Joint Venture its technology relating to the production of Astaxanthin and assets related thereto. These assets will continue to be used by the Joint Venture in the same manner as historically used by the Company. The Company and Tate each have a 50% ownership interest in the Joint Venture and equal representation on the Board of Directors of the Company. In addition, unamortized production costs in the amount of \$316,869 were contributed to the Joint Venture by Igene.

On April 3, 2003, the Board of Directors, in lieu of additional compensation, authorized the payment of shares to Mr. Stephen Hiu and Mr. Patrick Monahan. Each of them was awarded 83,333 shares of Igene common stock. The aggregate 166,666 shares was issued and expensed based on market value at the time of award, \$.060 per share, or \$10,000 of combined compensation.

During the course of 2004, \$295,000 of the \$1,000,000 of Convertible Debentures issued as part of the 2001 ProBio purchase, were converted to common stock. These shares were converted at \$.10 per share for a total of 2,950,000 shares. These shares were issued and the notes cancelled. This relieved the Company of \$295,000 of long-term debt.

IGENE Biotechnology, Inc. and Subsidiary
Notes to Consolidated Financial Statements
For the years ended December 31, 2004 and 2003

During the course of 2004 and 2003, Fermic, Igene's manufacturing agent, earned 3,640,792 and 2,785,957 shares, respectively, of common stock as part of the manufacturing agreement. Fermic earns 2,250 shares of common stock for each kilogram pure astaxanthin produced and delivered as part of the agreement. The average price is based on the market value of the shares at the time the product was produced. Fermic can earn up to 20,000,000 shares in total under the contract. The 3,640,792 shares were earned at an average price of \$.11 per share for 2004, and 2,785,957 shares were earned at an average price of \$.05 per share for 2003. Through December 31, 2004, 14,730,014 shares have been earned. Any future shares earned by Fermic will be issued on a quarterly basis.

On February 4, 2003, Igene sold its subsidiary ProBio to Fermtech AS in exchange for aggregate consideration valued at approximately \$343,000, consisting of 7,000,000 shares of Igene common stock that ProBio owned (2,000,000 shares were re-earned by Fermtech as described below), valued for the purposes of the acquisition at \$.03 per share, plus forgiveness of approximately \$168,000 of debt that Igene owed to ProBio at the time of purchase in 2001. Mr. Benjaminsen remained employed by Igene through February 2004, therefore 1,000,000 of the escrowed shares of common stock were delivered to Fermtech. As Mr. Benjaminsen remained employed by Igene through February 2005, the remaining 1,000,000 escrowed shares were being released from escrow and delivered to Fermtech in 2005.

During 2003, the Company extended scheduled repayment on demand notes of \$6,043,659 and related accrued interest of \$2,865,810 until March 31, 2006.

In April of 2004 the holder of preferred stock Series B, converted the 187,500 shares of preferred stock at a rate of two for one into 375,000 shares of common stock at a value of \$4.00 per share. The preferred shares were retired and the common shares issued.

During 2004 and 2003, 7,096 and 550 shares respectively of redeemable preferred stock were exercised and retired in exchange for 14,192 and 1,100 new shares respectively of common stock which were issued pursuant to the conversion.

During 2003, 3,750,000 warrants were exercised using \$200,892 of 8% notes payable and \$80,358 of accrued interest in a cashless exercise. 3,750,000 new shares of common stock were issued pursuant to these exercises of options and \$200,892 of 8% notes were cancelled.

During 2004 and 2003, Igene recorded dividends in arrears on 8% redeemable preferred stock at \$.64 per share aggregating \$12,981 and \$16,387 respectively, on Series A preferred stock which has been removed from paid-in capital and included in the carrying value of the redeemable preferred stock. (see also note 9)

(3) Concentration of Credit Risk

The Joint Venture is potentially subject to the effects of a concentration of credit risk in accounts receivable. Accounts receivable is substantially composed of receivables from customers in Chile, which is an important market for Igene's product, AstaXin®. Chile has from time to time experienced political unrest and currency instability. Because of the volume of business transacted by the Joint Venture in Chile, recurrence of such unrest or instability could adversely affect the businesses of its customers in Chile or the Joint Venture's ability to collect its receivables from these customers. In order to minimize risk, the Joint Venture strictly evaluates the companies to which it extends credit and all prices are denominated in US dollars as to minimize currency fluctuation risk. Losses due to credit risks in accounts receivable are expected to be immaterial.

IGENE Biotechnology, Inc. and Subsidiary
Notes to Consolidated Financial Statements
For the years ended December 31, 2004 and 2003

(4) Property and Equipment

Property and equipment are stated at cost and are summarized as follows:

Laboratory equipment and fixtures	\$ 181,043
Pilot plant equipment and fixtures	91,503
Idle equipment	56,150
Office furniture and fixtures	<u>36,990</u>
	365,685
Less accumulated depreciation	<u>(240,781)</u>
	<u>\$ 124,904</u>

Idle equipment represents manufacturing equipment, which is not presently needed for production of AstaXin®. Igene plans to retain the equipment for use when needed due to increased production volume or failure of presently used equipment. This equipment is not currently being depreciated and its net carrying amount approximates its fair value.

(5) Investment in Joint Venture

On March 18 2003, the Company entered into a Joint Venture Agreement with Tate & Lyle Fermentation Products Ltd. (“Tate”) Pursuant to a Joint Venture Agreement, the Company and Tate agreed to form a joint venture (the “Joint Venture”) to manufacture, market and sell Astaxanthin and derivative products throughout the world for all uses other than as a nutraceutical or otherwise for direct human consumption. Tate contributed \$24,600,000 in cash to the Joint Venture, while the Company transferred to the Joint Venture its technology relating to the production of Astaxanthin and assets related thereto. These assets continue to be used by the Joint Venture in the same manner as historically used by the Company. The Company and Tate each have a 50% ownership interest in the Joint Venture and equal representation on the Board of Directors of the Venture. The value of the Company’s initial investment in the Joint Venture has been recorded at an amount equal to Igene’s historical book value. As the cost of the Company’s technology and intellectual property has been previously expensed and has a carrying amount of zero, the investment in the Joint Venture has been recorded with a book value of \$316,869, which represents the unamortized production costs contributed to the Joint Venture. Added to this was a purchase of common stock in the new venture of \$6,000.

Production utilizes Tate’s fermentation capability together with the unique technology developed by Igene. Part of Tate’s existing Selby, England, citric acid facility will be modified to produce up to 1,500 tons per annum of this product. Tate’s investment of approximately \$25 million includes certain of its facility assets currently used in citric acid production. Sales and cost of sales activity are now recorded as part of the earnings of unconsolidated venture.

As a result of the Joint Venture, the production, sales and marketing of Astaxanthin now takes place in the unconsolidated Joint Venture. From inception on March 18, 2003 through December 31, 2004, Igene’s portion of the Joint Venture’s net loss was \$4,887,500. The loss was a result of a 50% interest in the following: Gross profit from inception was a negative \$4,356,000 on sales of \$6,784,000, less manufacturing cost of \$11,140,000. Selling and general and administrative expenses were \$5,268,000 and interest expense was \$151,000. The resulting loss was \$9,775,000. Igene’s 50% portion of the Joint Venture loss was \$4,887,500.

Because the Company accounts for its investment in the Joint Venture under the equity method of accounting, it would ordinarily recognize it’s 50% equity interest in the loss of the Joint Venture. However, losses in the Joint Venture are recognized only to the extent of the Investment in and Advances to the Joint

IGENE Biotechnology, Inc. and Subsidiary
Notes to Consolidated Financial Statements
For the years ended December 31, 2004 and 2003

Venture. Losses in excess of this amount are suspended from recognition in the financial statement and carried forward to offset Igene's share of the Joint Venture's future income, if any.

At December 31, 2004, prior to the recognition of its share of the Joint Venture loss, Igene's investment in the Joint Venture consisted of \$322,869 and its net advances to the Joint Venture amounted to \$685,438, for a total of \$1,008,307. For the period March 18, 2003 through December 31, 2003, Igene recognized \$818,052 of its share of a \$914,494 loss in the Joint Venture. For the year ended December 31 2004, Igene recognized losses to the extent of the increase in the advance for that period of \$190,255. The remainder is suspended and will be carried forward to offset Igene's share of earnings from the Joint Venture, if any. The balance in the Advances to and Investment in Joint Venture account on the Company's financial statements is zero at December 31, 2004.

The following schedules display certain account balances of the joint venture as of December 31, 2004 and for the period since March 18, 2003 (inception).

	December 31, <u>2004</u> (Unaudited)
ASSETS	
CURRENT ASSETS	
Cash	\$ 1,769,000
Accounts Receivable	1,602,000
Inventory	<u>1,434,000</u>
	4,805,000
OTHER ASSETS	
Fixed Assets	20,765,000
Intellectual property	<u>24,614,000</u>
TOTAL ASSETS	<u>\$ 50,184,000</u>
LIABILITIES AND EQUITY	
CURRENT LIABILITIES	
Accounts payable and accrued expenses	\$ 5,883,000
Working capital loan	<u>5,347,360</u>
TOTAL LIABILITIES	11,230,360
Equity	<u>38,953,640</u>
TOTAL LIABILITIES AND EQUITY	<u>\$ 50,184,000</u>
	Period from initial investment to <u>December 31, 2004</u> (unaudited)
Net Sales	\$ 6,784,000
Less: manufacturing cost	<u>(11,140,000)</u>
Gross Profit (Loss)	(4,356,000)
Less: selling, general and administrative	<u>(5,268,000)</u>
Operating Loss	(9,624,000)
Interest Expense	<u>(151,000)</u>
Net Loss	<u>\$ (9,775,000)</u>
Igene's 50% equity interest in the net loss	\$ (4,887,500)
Igene's Investment in and Advances to the Joint Venture	<u>\$ (1,008,307)</u>
Igene's suspended loss	<u>\$ (3,879,193)</u>

IGENE Biotechnology, Inc. and Subsidiary
Notes to Consolidated Financial Statements
For the years ended December 31, 2004 and 2003

	Year Ended <u>December 31, 2004</u>	Period from March 18, 2003 to <u>December 31, 2003</u>
Net Sales	\$ 5,650,000	\$ 1,134,000
Less: manufacturing cost	<u>(9,989,000)</u>	<u>(1,151,000)</u>
Gross Profit (Loss)	(4,339,000)	(17,000)
Less: selling, general and admin	<u>(3,440,000)</u>	<u>(1,828,000)</u>
Operating Loss	(7,779,000)	(1,845,000)
Interest Expense	<u>(167,000)</u>	<u>16,000</u>
Loss before tax	<u>\$ (7,946,000)</u>	<u>\$ (1,829,000)</u>
50% equity interest Igene	<u>\$ (3,973,000)</u>	<u>\$ (914,494)</u>
Igene's additional Investment in and Advances to the Joint Venture	<u>\$ (190,255)</u>	<u>\$ (818,052)</u>
Igene's incremental suspended loss	<u>\$ (3,782,745)</u>	<u>\$ (96,442)</u>

As a result of the Joint Venture, the production, sales and marketing of Astaxanthin now take place in the unconsolidated Joint Venture. For the years ended 2004 and 2003, Igene's portion of the Joint Venture loss was \$3,973,000 and \$914,494, respectively .

(6) Convertible Debentures

In 2002, Igene issued and sold \$250,000 in aggregate principal amount of 8% demand notes to certain directors of Igene. During 2003 Igene repaid these notes plus accrued interest in satisfaction of the debt.

On July 17, 2002, Igene issued and sold \$300,000 in aggregate principal amount of 8% convertible debentures, 50% each to certain directors of Igene. These debentures are convertible into shares of Igene's common stock at \$.03 per share based on the market price of Igene's shares at the time the debentures were agreed to. In consideration of the commitment to purchase the 8% convertible debenture, these directors also received an aggregate of 10,000,000 warrants to purchase common stock at \$.03 per share. These debentures, if not converted earlier, become due on July 17, 2012.

On February 22, 2002, Igene issued and sold \$1,000,000 in aggregate principal amount of 8% convertible debentures, 50% each to certain directors of Igene. These debentures are convertible into shares of Igene's common stock at \$.04 per share based on the market price of Igene's shares at the time the debentures were agreed to. In consideration of the commitment to purchase the 8% convertible debenture, these directors also received an aggregate of 25,000,000 warrants to purchase common stock at \$.04 per share. These debentures, if not converted earlier, become due on February 22, 2012.

In March 2001, Igene issued \$1,014,211 of 8%, 10-year, convertible debentures to certain directors of Igene in exchange for the cancellation of \$800,000 of demand notes payable (including accrued interest of \$14,212) and \$200,000 in cash. \$600,000 of these demand notes were issued during 2000 and \$200,000 were issued subsequently. These debentures are convertible into 10,142,110 shares of Igene's common stock at \$.08 per share. These directors also received 10,142,110 warrants to purchase common stock at \$.08 per share. Interest is payable at maturity.

In March 2001, certain directors of Igene also committed to provide additional funding in the form of 8%, 10-year, convertible debentures in the amount of \$1,500,000. In consideration of this commitment, these directors also received 18,750,000 warrants to purchase common stock at \$.08 per share. These debentures

IGENE Biotechnology, Inc. and Subsidiary
Notes to Consolidated Financial Statements
For the years ended December 31, 2004 and 2003

are convertible into 18,750,000 shares of Igene's common stock at \$.08 per share. Interest is payable at maturity.

In December 2001, Igene issued \$1,000,000 of 6%, 3-year convertible debentures in connection with the purchase of ProBio, now known as Igene Norway AS. These convertible debentures are convertible into the Company's stock at a price of \$.10 per share, 10,000,000 shares in total. Accrued interest on this note is due every six months. Of these \$295,000 have been converted to common stock.

Convertible debentures are summarized as follows as of December 31, 2004:

	<u>Principal</u>	<u>Accrued Interest</u>
8%, 10-year, convertible debenture issued 7/17/02	\$ 300,000	\$ 58,719
8%, 10-year, convertible debenture issued 2/22/02	1,000,000	224,877
8%, 10-year, convertible debenture issued 3/1/01	1,014,212	310,863
8%, 10-year, convertible debenture issued 3/27/01	1,500,000	414,180
10%, 3-year, convertible debenture issued 11/30/01	<u>705,000</u>	<u>11,750</u>
	\$ 4,519,212	\$1,020,389
Less current maturities	<u>(705,000)</u>	<u>(11,750)</u>
	<u>\$ 3,814,212</u>	<u>\$1,008,639</u>

(7) **Notes Payable**

This long term debt, approximately \$5,800,000 which was scheduled to become payable in March 2003, has been extended and is now due March 2006. Management felt any attempts to satisfy the debt on it's original due date would have had materially adverse effects on the Company.

As a part of the terms of the debt, the exercise prices of the warrants and any conversion features was discounted by 25% thus a \$.10 warrant is now convertible at \$.075 cents.

Beginning November 16, 1995 and continuing through May 8, 1997, Igene issued promissory notes to certain directors for aggregate consideration of \$1,082,500. These notes specify that at any time prior to repayment the holder has the right to convert the notes to common stock of Igene at prices ranging from \$0.05 per share to \$0.135 per share, based on the market price of common shares at the respective issue dates. The notes were convertible in total to 13,174,478 shares of common stock. As a result of the extension they are now convertible to 17,565,970 shares of common stock. Concurrently, with each of the \$1,082,500 of promissory notes, the holders also received 13,174,478 warrants for an equivalent number of shares at the equivalent price per share. The warrants expire ten years from the issue of the notes. As a result of the extension of debt the warrant exercise prices were reduced by 25%. These notes were modified in conjunction with the 1998 rights offering to be due on March 31, 2003, and have been extended to March 31, 2006 as part of the extension. The notes bear interest at the prime rate.

In conjunction with the rights offering in March 1998, Igene issued \$5,000,000 of 8% Notes due March 31, 2003 and 50,000,000 warrants to purchase one share of common stock at an exercise price of \$.10 per share expiring March 31, 2008. As a result of the extension these notes are now due March 31, 2006 and the exercise price is now \$.075 per share.

IGENE Biotechnology, Inc. and Subsidiary
Notes to Consolidated Financial Statements
For the years ended December 31, 2004 and 2003

Notes Payable are summarized as follows as of December 31, 2004:

	Principal	Accrued Interest
Long-term unsecured notes payable, bearing interest at prime, scheduled to mature March 31, 2003, extended to March 31, 2006, convertible into common stock	\$ 1,082,500	\$ 567,421
Long-term unsecured notes payable, bearing interest at 8%, scheduled to mature March 31, 2003, extended to March 31, 2006	<u>4,759,767</u>	<u>2,572,621</u>
	<u>\$ 5,842,267</u>	<u>\$ 3,140,042</u>

Combined aggregate amounts of maturities for all convertible debentures and notes payable are as follows:

Year	Amount
2005	\$ 705,000
2006	---
2007	5,842,267
2008	---
2009	---
Thereafter	\$ 3,814,212

(8) Redeemable Preferred Stock

Each share of redeemable preferred stock is entitled to vote on all matters requiring shareholder approval as one class with holders of common stock, except that each share of redeemable preferred stock is entitled to two votes and each share of common stock is entitled to one vote.

Redeemable preferred stock is convertible at the option of the holder at any time, unless previously redeemed, into shares of Igene's common stock at the rate of two shares of common stock for each share of preferred stock (equivalent to a conversion price of \$4.00 per common share), subject to adjustment under certain conditions.

Shares of redeemable preferred stock are redeemable for cash in whole or in part at the option of Igene at any time at the stated value plus accrued and unpaid dividends to the redemption date. Dividends are cumulative and payable quarterly on January 1, April 1, July 1 and October 1, since January 1, 1988.

The preferred shares, Series B, were retired and the common shares issued. This relieved Igene of debt recorded at \$1,650,000 as of December 31, 2003.

Mandatory redemption of preferred stock Series A was by agreement due by Igene in October 2002. As Igene is operating at a negative cash flow and negative earnings, Maryland law does not allow for the redemption of these shares. As such they will remain outstanding and continue to accrue dividends until such time as Igene is able to undertake redemption, though there can be no assurance this will develop.

In December 1988, as part of an overall effort to contain costs and conserve working capital, Igene suspended payment of the quarterly dividend on its preferred stock. Resumption of the dividend will require significant improvements in cash flow. Unpaid dividends cumulate for future payment or addition to the liquidation preference or redemption value of the preferred stock. As of December 31, 2004, total dividends in arrears on Igene's preferred stock equal \$192,494 (or \$10.40 per share) on Igene's Series A and are included in the carrying value of the redeemable preferred stock.

IGENE Biotechnology, Inc. and Subsidiary
Notes to Consolidated Financial Statements
For the years ended December 31, 2004 and 2003

(9) **Stockholders' Equity**

Options

In June of 2001, the stockholders approved the 2001 Stock Option Plan (the "2001 Plan"), which succeeds the 1997 Stock Option Plan (the "1997 Plan"), which succeeded Igene's 1986 Stock Option Plan (the "1986 Plan"), as amended. All outstanding, unexercised options granted under the 1997 and 1986 Plans remain outstanding with unchanged terms. The number of shares authorized for issuance under the 2001 Plan is 55,000,000. This is in addition to the 20,000,000 shares authorized for issuance under the 1997 Plan, and the 2,000,000 shares authorized for issuance under the 1986 Plan.

The following is a summary of options granted and outstanding under the plans as of December 31, 2004 and 2003:

	2004		2003	
	Number	Weighted Average Exercise Price	Number	Weighted Average Exercise Price
Options outstanding and exercisable, beginning of year	35,488,250	\$.047	35,588,250	\$.047
Options granted	11,989,500	\$.010	---	---
Options exercised	(550,000)	\$.025	(100,000)	\$.025
Options forfeited, or withdrawn with consent of holders	---	---	---	---
Options expired	---	---	---	---
Options outstanding and exercisable, end of year	46,927,750	\$.061	35,488,250	\$.047

Options Outstanding

<u>Exercise Price</u>	<u>Shares</u>	<u>Weighted Average Remaining Life (Years)</u>
\$.025	16,550,000	7.6
\$.050	9,342,666	4.9
\$.053	97,719	2.0
\$.060	162,865	2.0
\$.065	45,000	4.5
\$.080	5,500,000	6.8
\$.100	11,989,000	9.6
\$.100	3,240,000	3.3
\$.061	46,927,750	

IGENE Biotechnology, Inc. and Subsidiary
Notes to Consolidated Financial Statements
For the years ended December 31, 2004 and 2003

In addition to the options listed above, the following additional unregistered options were issued outside of the 2001, 1997 and 1986 plans. Per Benjaminsen and Stein Ulve, were each granted 10,000,000 options, as part of their Igene employment agreement signed concurrently with the ProBio purchase. The options vest over a three year period. Mr. Ulve had vested in the first third of his options and with his resignation from Igene forfeited the balance. He had until January 21, 2004 to exercise the options that had vested, 200,000 were exercised and the shares issued, the balance was forfeited. Mr. Benjaminsen has vested in his options. These options expire October 9, 2011. All options were exercised or were exercisable at \$0.08 per share.

Warrants

In consideration for his work on the Board of Directors Mr. Kimelman was awarded on May 13, 2003 11,000,000 warrants to purchase Igene common stock at \$.06 per share. The warrants shall expire March 26, 2013.

The following table summarizes warrants issued, outstanding and exercisable:

	As of December 31,	
	2004	2003
Issued	205,261,073	205,266,073
Outstanding	205,261,073	205,266,073
Exercisable	205,261,073	205,266,073

Common Stock

At December 31, 2004, 205,261,073 shares of authorized but unissued common stock were reserved for exercise of outstanding warrants, 46,927,750 shares of authorized but unissued common stock were reserved for exercise pursuant to the 1986, 1997 and 2001 Stock Option Plans, 10,000,000 shares were reserved for exercise of options held by Mr. Benjaminsen, 37,018 shares of authorized but unissued common stock were reserved for issuance upon conversion of Igene's outstanding preferred stock, 5,269,986 shares were reserved for issue in accordance with Igene's manufacturing agreement with Fermic (see note 11) and 91,043,621 shares of authorized but unissued stock were reserved for issuance upon conversion of outstanding convertible notes.

Preferred Stock

In April of 2004 the holder of the Series B preferred stock, converted the 187,500 shares of preferred stock at a rate of two for one into 375,000 shares of common stock at a value of \$4.00 per share. The preferred shares were retired and the common shares issued. This relieved Igene of debt recorded at \$1,650,000 as of December 31, 2003.

As of December 31, 2004, total dividends in arrears on Igene's preferred stock equal \$192,494 (or \$10.40 per share) on Igene's Series A and are included in the carrying value of the redeemable preferred stock.

(10) Net Loss Per Common Share

Net loss per common share for 2004 and 2003 is based on 96,609,848 and 88,474,552 weighted average shares, respectively. For purposes of computing net loss per common share, the amount of net loss has been increased by dividends declared and cumulative undeclared dividends in arrears on preferred stock.

IGENE Biotechnology, Inc. and Subsidiary
Notes to Consolidated Financial Statements
For the years ended December 31, 2004 and 2003

Common stock equivalents, including: options, warrants, convertible debt, convertible preferred stock, and exercisable rights have not been included in the computation of earnings per share in 2004 and 2003 because to do so would have been anti-dilutive. However, these common stock equivalents could have potentially dilutive effects in the future.

(11) Commitments

Igene is obligated for office and laboratory facilities and other rentals under operating lease agreements, which expire in 2011. The base annual rentals are approximately \$94,000, increasing to \$106,000 by the end of the lease term, plus the Company's share of taxes, insurance and other costs. Annual rent expense relating to the leases for the years ended December 31, 2004 and 2003 approximated \$113,000 and \$94,000, respectively.

Future minimum rental payments, in the aggregate and for each of the next five years are as follows:

<u>Year</u>	<u>Amount</u>
2005	\$ 94,000
2006	96,000
2007	98,000
2008	101,000
2009	103,000
Thereafter	<u>114,000</u>
	<u>\$ 606,000</u>

Effective May 20, 2000, Igene signed an exclusive manufacturing agreement with Fermic, S.A. de C.V. ("Fermic"), of Mexico City, Mexico, for the production of AstaXin®. The Fermic contract provides that the manufacturer has a limited exclusive right to produce AstaXin® and is paid a monthly fee in cash, which is based on manufacturing capacity, plus shares of Igene common stock based on production quantities. Fermic provides equipment and facilities necessary to manufacture and store the product and is responsible for purchasing raw materials. Igene is responsible for sales efforts and for ensuring the quality of the pigment. Igene also has a role in ensuring that the manufacturing process works effectively. The term of the contract is 6 years.

Based on production of AstaXin®, Igene has committed to issue to Fermic up to a maximum of 20,000,000 shares of Igene common stock during a six year period expiring May 20, 2006 in accordance with the manufacturing agreement. Based on quantities of AstaXin® produced, 14,730,014 shares of Igene common stock has been issued to Fermic. Since the inception of the agreement stock has been recorded as a manufacturing expense and also as an increase in common stock and additional paid in capital of \$1,005,024. This amount has been computed based on the fair value of the stock as of the period in which the shares were earned.

(12) Income Taxes

No income tax benefit or deferred tax asset is reflected in the financial statements. Deferred tax assets are recognized for future deductible temporary difference and tax loss carry forwards if their realization is "more likely than not".

At December 31, 2004 Igene has federal and state net operating loss carry-forwards of approximately \$22,000,000 that expire at various dates from 2004 through 2024. The recorded deferred tax asset, representing the expected benefit from the future realization of the net operating losses, net of the valuation allowance, was \$-0- for 2004 and 2003.

IGENE Biotechnology, Inc. and Subsidiary
Notes to Consolidated Financial Statements
For the years ended December 31, 2004 and 2003

The sources of the deferred tax asset are approximately as follows:

Net operating loss carry-forward benefit	\$	8,580,000
Valuation allowance		<u>(8,580,000)</u>
Deferred tax asset, net	\$	<u>---</u>

(13) Uncertainty

Igene has incurred net losses in each year of its existence, aggregating approximately \$44,400,000 from inception to December 31, 2004 and its liabilities and redeemable preferred stock exceeded its assets by approximately \$14,445,000 at that date. These factors indicate that Igene will not be able to continue in existence unless it is able to raise additional capital and attain profitable operations.

On March 18 2003, the Company entered into a Joint Venture Agreement with Tate & Lyle Fermentation Products Ltd. (“Tate”) Pursuant to a Joint Venture Agreement, the Company and Tate agreed to form a joint venture (the “Joint Venture”) to manufacture, market and sell Astaxanthin and derivative products throughout the world for all uses other than as a Nutraceutical or otherwise for direct human consumption. Tate contributed \$24,600,000 in cash to the Joint Venture, while the Company transferred to the Joint Venture its technology relating to the production of Astaxanthin and assets related thereto. These assets continue to be used by the Joint Venture in the same manner as historically used by the Company. The Company and Tate each have a 50% ownership interest in the Joint Venture and equal representation on the Board of Directors of the Company. The value of the Company’s investment in the Joint Venture has been recorded at an amount equal to the book value of the Registrant’s consideration contributed at the creation of the Joint Venture.

Igene believes that should this Joint Venture be able to reach a profitable manufacturing level, eventually gross profits, and subsequently profitable operation, can be achieved.

(14) Nature of Risks and Concentrations

Revenue during 2004 and 2003 were derived from sales of the product, AstaXin®. The majority of the Joint Venture’s and Igene’s 2004 and 2003 sales were to fish producers in the aquaculture industry in Chile.

The preceding concentrations subject Igene to certain risks. For example, it is considered at least reasonably possible that any particular customer, distributor, product line, or provider of services or facilities could be lost in the near term. It is also considered at least reasonably possible that operations located outside the United States could be disrupted in the near term. However, Igene has at present no information that would lead it to believe that it will lose its principal product, principal customers, or its contracted manufacturer; or that its operations in Mexico City or Chile will be disrupted, though this belief can not be assured.

(15) Simple Retirement Plan

Effective January 1, 1997, Igene adopted a Simple Retirement Plan under Internal Revenue Code Section 408(p). The Plan is a defined contribution plan, which covers all of Igene’s U.S. employees who receive at least \$5,000 of compensation for the preceding year. The Plan permits elective employee contributions. Effective January 1, 2003, Igene made an elective contribution of 3% of each eligible employee’s compensation for each year. Igene’s contributions to the plan for 2004 and 2003 were \$19,221 and 17,631, respectively.

SIGNATURES

In accordance with Section 13 or 15(d) of the Securities Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in Howard County, Maryland on March 26, 2004.

IGENE Biotechnology, Inc.

(Registrant)

By /s/ STEPHEN F. HIU
STEPHEN F. HIU
President, Chief Technical Officer
and Treasurer

Date October 06, 2005

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

<u>Signature</u>	<u>Title</u>	<u>Date</u>
<u>/s/ STEPHEN F. HIU</u> STEPHEN F. HIU	Director, President, Chief Technical Officer, Treasurer	October 06, 2005
<u>/s/ EDWARD J. WEISBERGER</u> EDWARD J. WEISBERGER	Chief Financial Officer (principal financial and accounting officer)	October 06, 2005
<u>/s/ THOMAS L. KEMPNER</u> THOMAS L. KEMPNER	Vice Chairman of Board of Directors	October 06, 2005
<u>/s/ MICHAEL G. KIMELMAN</u> MICHAEL G. KIMELMAN	Chairman of the Board of Directors	October 06, 2005
<u>/s/ SIDNEY R. KNAFEL</u> SIDNEY R. KNAFEL	Director	October 06, 2005
<u>/s/ PATRICK F. MONAHAN</u> PATRICK F. MONAHAN	Director, Vice President Secretary and Director of Manufacturing	October 06, 2005

EXHIBIT 23.a.

CONSENT OF INDEPENDENT AUDITORS

We hereby consent to the incorporation by reference in the Registration Statements Nos. 333-76616, 333-65013 and 333-6103 each on Form S-8 and to Registration Statement No. 333-45218 on Form S-3, and in the Annual Report on Form 10-KSB of Igene Biotechnology, Inc. for the year ended December 31, 2004 of our report dated March 25, 2005, relating to the consolidated financial statements of Igene Biotechnology, Inc.

/s/ BERENSON LLP

BERENSON LLP

New York, New York
October 03, 2005

EXHIBIT 23.b.

CONSENT OF REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements Nos. 333-76616, 333-65013 and 333-6103 each on Form S-8 and to Registration Statement No. 333-45218 on Form S-3, and in the Annual Report on Form 10-KSB of Igene Biotechnology, Inc. for the year ended December 31, 2003 of our report dated August 18, 2005, relating to the consolidated financial statements of Igene Biotechnology, Inc.

/s/ STEGMAN & COMPANY

STEGMAN & COMPANY

Baltimore, Maryland
October 03, 2005

EXHIBIT 31.1

I, Stephen F. Hiu, certify that:

1. I have reviewed this Annual report on Form 10-KSB for fiscal year 2004 of Igene Biotechnology, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - c) Disclosed in this report any change in the small business issuer's internal control financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and
5. The small business issuer's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting.

Date: October 06, 2005

/s/ STEPHEN F. HIU

STEPHEN F. HIU
President

EXHIBIT 31.2

I, Edward J. Weisberger, certify that:

1. I have reviewed this Annual report on Form 10-KSB for fiscal year 2004 of Igene Biotechnology, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - c) Disclosed in this report any change in the small business issuer's internal control financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and
5. The small business issuer's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting.

Date: October 06, 2005

/s/ EDWARD J. WEISBERGER

EDWARD J. WEISBERGER
Chief Financial Officer

EXHIBIT 32.1

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the IGENE Biotechnology, Inc. (the "Company") Annual Report on Form 10-KSB for the period ended December 31, 2004, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Stephen F. Hiu, President of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 06, 2005

By: /s/ STEPHEN F. HIU

STEPHEN F. HIU
President

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EXHIBIT 32.2

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the IGENE Biotechnology, Inc. (the "Company") Annual on Form 10-KSB for the period ended December 31, 2004, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Edward J. Weisberger, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 06, 2005

By: /s/ EDWARD J. WEISBERGER

EDWARD J. WEISBERGER
Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.